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“Stillness, insight, and wisdom 
arise only when we can settle 
into being complete in this 
moment, without having to seek 
or hold on to or reject anything.” 
 
 
- Jon Kabat-Zinn 
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Abstract 
Serum parathyroid hormone (PTH) and vitamin D are the major regulators of extracellular 
calcium homeostasis. The inverse association between PTH and vitamin D and the 
common age-related elevation of the PTH concentration are well known phenomena. 
However, the confounding or modifying factors of this relationship and their impact on 
the response of PTH levels to vitamin D supplementation need further investigation. 
Clinical conditions such as primary hyperparathyroidism (PHPT), renal failure and 
vitamin D deficiency, characterized by an elevation of the PTH concentration, have been 
associated with impaired long-term health outcomes. Curative treatments for these 
conditions have also been shown to decreases PTH concentration and attenuate some of 
the adverse health effects. In PHPT it has also been commonly held that hypercalcaemia, 
the other hallmark of the disease, is the key mediator of the adverse health outcomes. In 
chronic kidney disease the systemic vascular disease has been proposed to have the most 
important impact on general health. Some evidence also indicates that vitamin D may have 
significant extraskeletal actions. 
However, the frank elevation of PTH concentration seen in advanced PHPT and in 
end-stage renal failure have also been suggested to be at least partly causally related to an 
increased risk of death as well as cognitive dysfunction. However, the exact mechanisms 
have remained unclear. Furthermore, the predictive value of elevated PTH in unselected 
older populations has been less well studied. 
The studies presented in this thesis investigated the impact of age and mobility on the 
responses of PTH levels to vitamin D deficiency and supplementation. Furthermore, the 
predictive value of PTH for long-term survival and cognitive decline was addressed in an 
unselected population of older people. The hypothesis was that age and chronic 
immobility are related to a persistently blunted elevation of PTH concentration, even in 
the presence of chronic vitamin D deficiency, and to attenuated responses of PTH to 
vitamin D supplementation. It was also further hypothesized that a slightly elevated or 
even high-normal PTH concentration is an independent indicator of an increased risk of 
death and cognitive decline in the general aged population. 
The data of this thesis are based on three samples: a meta-analysis of published 
vitamin D supplementation trials, a randomized placebo controlled six-month vitamin D 
supplementation trial, and a longitudinal prospective cohort study on a general aged 
population. Based on a PubMed search, a meta-analysis of 52 clinical trials with 6 290 
adult participants was performed to evaluate the impact of age and immobility on the 
responses of PTH to 25-OHD levels and vitamin D supplementation. A total of 218 
chronically immobile, very old inpatients were also enrolled into a vitamin D 
supplementation trial. Mortality data for these patients was also collected after a two-year 
follow-up. Finally, data from the Helsinki Aging Study, which followed three random age 
cohorts (75, 80 and 85 years) until death in almost all subjects, was used to evaluate the 
predictive value of PTH for long-term survival and cognitive decline. 
This series of studies demonstrated that in older people without overt renal failure or 
severe hypercalcaemia, serum 25-OHD and PTH were closely associated, but this 
relationship was also affected by age and immobility. Furthermore, a substantial 
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proportion of old chronically bedridden patients did not respond to vitamin D deficiency 
by elevating PTH, and the effect of a high-dose (1200 IU/d) six-month cholecalciferol 
supplementation on the PTH concentration was minor. This study demonstrated 
longitudinally for the first time that the blunted PTH also persisted over time. Even a 
subtle elevation of PTH to high-normal levels predicted impaired long-term health 
outcomes. Slightly elevated PTH concentrations indicated an increased risk of clinically 
significant cognitive decline and death during the last years of life in a general aged 
population. This association was also independent of serum ionized calcium (Ca2+) and the 
estimated glomerular filtration rate (GFR). A slightly elevated PTH also indicated 
impaired two-year survival during the terminal years of frail elderly subjects 
independently of Ca2+, GFR, and of 25-OHD levels. 
The interplay between PTH and vitamin D in the regulation of calcium homeostasis is 
more complex than has been generally considered. In addition to muskuloskeletal health 
parathyroid hormone is also related to the maintenance of other important domains of 
health in old age. Higher PTH concentrations, even within conventional laboratory 
reference ranges, seem to be an independent indicator of an increased risk of all-cause and 
of cardiovascular mortality, independently of established cardiovascular risk factors, 
disturbances in mineral metabolism, and renal failure. Limited and inconsistent evidence 
supports the role of vitamin D deficiency-related lack of neuroprotective effects over the 
causal association between PTH and impaired cognitive functions. However, the causality 
of these associations remains unclear. The clinical implications of the observed 
relationships remain to be elucidated by future studies interfering with PTH 
concentrations, especially by long-term interventions to reduce PTH.  
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Tiivistelmä 
Parathormoni (PTH) eli lisäkilpirauhashormoni ja D-vitamiini ovat keskeisiä solun 
ulkoisen kalsiumtasapainon säätelijöitä. PTH:n ja D-vitamiinin välinen käänteinen yhteys 
sekä ikääntymiseen liittyvä PTH-pitoisuuksien nousu ovat hyvin tunnettuja ilmiöitä. 
PTH:n ja D-vitamiinin välistä yhteyttä sekoittavia ja muokkaavia tekijöitä on 
systemaattisesti tutkittu kuitenkin varsin vähän, eikä näiden tekijöiden merkitystä D-
vitamiinikorvaushoidon PTH-vasteisiin tunneta kunnolla. 
 Korkean PTH-pitoisuuden syynä on yleensä primaarinen hyperparatyreoosi (PHPT), 
munuaisten vajaatoiminta tai D-vitamiinin puutos. Näiden kliinisten tilojen on havaittu 
olevan yhteydessä moniin yleisiin ja terveyttä merkittävästi heikentäviin sairauksiin. PTH-
pitoisuuden laskuun johtavien interventioiden on myös osoitettu ainakin osittain 
lieventävän näitä sairauksia. PHPT-potilaiden hyperkalsemiaa on pidetty keskeisenä 
välittävänä tekijänä näiden terveyshaittojen patofysiologiassa. Munuaisten 
vajaatoiminnassa taas koko verisuoniston inflammatorisen prosessin on ajateltu johtavan 
yleiseen terveyden heikentymiseen. Näyttöä on myös jonkin verran D-vitamiinin 
yhteyksistä luuston ja lihaksiston ulkopuoliseen terveyteen. Vaikeaan PHPT:iin ja 
munuaisten vajaatoimintaan liittyvän voimakkaan PTH-pitoisuuden nousun itsessään on 
ajateltu ainakin osittain lisäävän kuoleman riskiä ja heikentävän kognitiota. Mahdollisten 
vaikutusmekanismien yksityiskohdat ovat kuitenkin toistaiseksi jääneet tuntemattomiksi. 
Huomionarvoista on myös, että etenkin vanhuksilla yleisesti esiintyvän lievästi kohonneen 
PTH-pitoisuuden merkitys terveydelle on tunnettu huonommin. 
Tämän väitöskirjan osatutkimukset tarkastelivat iän ja liikuntakyvyn vaikutusta 
ikääntyneiden PTH-vasteeseen sekä D-vitamiinin puutteen että D-vitamiinikorvaushoidon 
aikana. Myös PTH:n ennustevaikutus lisääntyneen kuolleisuuden ja kognition 
heikentymisen riskille selvitettiin valikoimattomassa ikääntyneiden ihmisten aineistossa. 
Tutkimusten hypoteeseina oli: 1.) Ikääntyminen ja krooninen liikuntakyvyttömyys ovat 
yhteydessä PTH-pitoisuuden nousun pysyvään vaimentumiseen D-vitamiinin puutteessa. 
2.) Ikääntyminen ja krooninen liikuntakyvyttämyys vaimentavat D-
vitamiinikorvaushoidon PTH-pitoisuutta laskevaa vaikutus. 3.) Lievästi kohonnut tai jopa 
vain viitealueen ylärajoilla oleva PTH-pitoisuus on yhteydessä lisääntyneeseen kuoleman 
ja kognition heikentymisen riskiin ikääntyneessä väestössä. 
Väitöskirja perustuu kolmeen eri aineistoon; julkaistujen D-vitamiinikorvaushoito-
tutkimusten meta-analyysiin, satunnaistettuun lumekontrolloituun kuuden kuukauden D-
vitamiinikorvaushoitotutkimukseen ja helsinkiläisen ikääntyneiden väestökohortin 
pitkittäisseurantaan. PubMed hakuun perustuen meta-analyysiin valittiin 52 kliinistä D-
vitamiinikorvaushoitotutkimuksen interventioryhmää, joihin osallistui yhteensä 6290 
potilasta. Yhteensä 218 kroonisesti liikuntakyvytöntä ikääntynyttä potilasta rekrytoitiin 
kuuden kuukauden mittaiseen lumekontrolloituun D-vitamiinikorvaushoitotutkimukseen. 
Näiden potilaiden kuolleisuustiedot kerättiin myös kahden vuoden seurannan jälkeen. 
PTH:n pitkäaikaisen ennustevaikutuksen arvioimiseksi väitöskirjassa hyödynnettiin 
Helsingin Vanhustutkimuksen aineistoa, jossa kolmea ikäkohorttia (75-vuotiaat, 80-
vuotiaat ja 85-vuotiaat) seurattiin kuolemaan saakka miltei kaikkien osallistujien kohdalla. 
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Tämä tutkimusten sarja osoittaa, että PTH ja D-vitamiinin varastomuodon (25-OHD) 
pitoisuudet ovat läheisessä yhteydessä keskenään ikääntyneillä, joilla ei ole todettu selkeää 
munuiasten vajaatoimintaa tai vaikeaa hyperkalsemiaa. PTH:n ja 25-OHD:n yhteys on 
kuitenkin riippuvainen myös ikääntymisestä ja liikuntakyvystä. Merkittävällä osalla 
ikääntyneistä kroonisesti liikuntakyvyttämistä potilaista PTH-pitoisuus pysyi suhteellisen 
matalana D-vitamiinin puutoksesta huolimatta. Tämä tutkimus osoitti myös ensimmäisen 
kerran, että vaimea PTH vaste säilyi ajan mittaan myös muuttumattomana. Kuuden 
kuukauden korkea-annoksisen (1200 IU/vrk) D-vitamiinikorvaushoidon vaikutus PTH-
pitoisuuteen on myös näillä potilailla vähäinen. Toinen tämän tutkimuksen merkittävä 
havainto on vain lievästi kohonneen tai jopa vain viitealueen ylärajoilla olevan PTH-
pitoisuuden yhteys lisääntyneeseen kuoleman ja kognition heikentymisen riskiin 
vanhusväestössä viimeisten elinvuosien aikana. Tämä yhteys osoittautui myös olevan 
seerumin ionisoituneesta kalsiumpitoisuudesta ja laskennallisesta munuaisten 
glomerulusten suodatusnopeudesta riippumaton. Lievästi kohonnut PTH-pitoisuus oli 
myös yhteydessä hauraiden terminaalivaiheen potilaiden lisääntyneeseen kuolleisuuteen 
kahden vuoden seurannassa. Tässä havainnoissa keskeistä oli se, että PTH 
ennustevaikutus osoittautui kalsiumin ja munuaistoiminnan lisäksi myös 25-OHD 
pitoisuudesta riippumattomaksi. 
Väitöskirjan havaintojen perusteella näyttää siltä, että lisäkilpirauhashormonin ja D-
vitamiinin välinen vuorovaikutus on monimutkaisempaa kuin mitä yleisesti on tähän asti 
ajateltu. Myös muiden tutkijaryhmien viimeaikaiset tulokset sopivat hyvin yhteen tämän 
väitöskirjan havaintojen kanssa, jotka tukevat myös näkemystä, jonka mukaan tunnettujen 
luustovaikutusten lisäksi PTH:lla näyttäisi olevan merkitystä myös muiden keskeisten 
terveyden osa-alueiden ylläpidossa ikäännyttäessä. Jo viitealueen ylärajoilla oleva PTH 
pitoisuus ennustaa lisääntynyttä kuoleman ja erityisesti kardiovaskulaarisen kuoleman 
riskiä. Nykyisen tutkimuksen valossa tämä ennustevaikutus on riippumaton niin 
perinteisistä kardiovaskulaarisista riskitekijöistä, mineraalimetabolian häiriöistä kuin 
munuaistoiminnastakin. Rajallisen ja osin ristiriitaisen nykyisen näytön perusteella D-
vitamiinin hermostoa suojaavat vaikutukset näyttävät merkittävimmiltä kuin PTH:n 
mahdolliset suorat vaikutukset. Lisääntyvästi kirjallisuudesta huolimatta näiden 
yhteyksien kausaalisuus on edelleen epäselvää ja niiden kliinisen merkityksen 
arvioimiseksi tarvittaisiin jatkotutkimuksia, jotka tähtäävät vaikuttamaan PTH 
pitoisuuksiin hoidollisin keinoin.  
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Abbreviations 
1.25-OHD 1.25-hydroxyvitamin D = calcitriol 
1α-OHase 1-alpha hydroxylase 
24-OHase Vitamin D-24-hydroxylase 
25-OHase Vitamin D-25-hydroxylase 
25-OHD 25-hydroxyvitamin D = calcidiol 
95%CI 95 percent confidence interval 
APOE Apolipoprotein E 
BMI Body mass index  
Ca2+ Serum ionized calcium 
CaSR Calcium-sensing receptor 
CaT Serum total calcium 
CDR Clinical dementia rating 
CPS Cognitive performance scale 
CV Coefficient of variation 
e.g. exempli gratia (for example) 
etc. et cetera 
FGF-23 Fibroblast growth factor 23 
GFR glomerular filtration rate 
GPCR G protein-coupled receptors 
HR Cox proportional hazard ratio 
i.e. id est (that is) 
ICTP  Carboxyl-terminal telopeptide of type I collagen 
IU International units 
LURIC Ludwigshafen risk and cardiovascular health study 
MMSE Mini-mental state examination 
N Number 
Na Sodium 
NHANES National health and nutrition examination survey 
OR Odds ratio 
P Phosphate 
PHPT Primary hyperparathyroidism 
PINP  Amino-terminal propeptide of type I procollagen 
PLC  Phospholipase C 
PTH Parathyroid hormone 
PTH1R  Parathyroid hormone receptor 1  
PTH2R Parathyroid hormone receptor 2 
r Pearson’s bivariate correlation coefficient 
RAS  renin-angiotensin system 
RIA Radioimmunoassay 
SHPT Secondary hyperparathyroidism 
SMR Standardized mortality ratio 
TIP39 Tuberoinfundibular peptide of 39 residues 
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TRPV5 Transient receptor potential vanilloid 5 channel 
TRPV6 Transient receptor potential vanilloid 6 channel 
UV-B  Ultraviolet B radiation 
VDBP Vitamin D-binding protein 
VDR Nuclear vitamin D receptor 
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1. INTRODUCTION 
Parathyroid hormone (PTH) is a circulating hormone comprised of 84 amino acids. It is 
produced in the parathyroid glands and primarily acts on bone and kidney to maintain 
extracellular calcium levels within normal limits. Its release from the parathyroid glands is 
triggered by hypocalcaemia and hyperphosphataemia. PTH stimulates osteoblast activity 
and increases renal tubular reabsorption of calcium. It also promotes the conversion of 25-
hydroxyvitamin D (25-OHD) to 1.25-hydroxyvitamin D (1.25-OHD) by 1-alpha 
hydroxylase in the kidney, leading to the increased gastrointestinal absorption of calcium. 
Classically, the biological activity has been thought to be carried out by 1.25-OHD, but 
25-OHD may also have direct effects. Hypercalcaemia and hypophosphataemia are the 
major suppressors of PTH synthesis and secretion. However, vitamin D also exerts 
negative feedback on PTH synthesis. 
Parathyroid disorders include increased activity, i.e. hyperparathyroidism, and 
decreased activity, i.e. hypoparathyroidism. Hyperparathyroidism has been classically 
classified as primary (PHPT) or secondary (SHPT), depending whether the cause of 
increased PTH secretion is found in the parathyroid glands themselves (hyperplasia or 
adenoma) or externally (chronic kidney disease or vitamin D deficiency). Long-standing 
SHPT may also lead to a PHPT-like condition, namely tertiary hyperparathyroidism, if the 
regulatory mechanisms of PTH synthesis and secretion are disrupted. Parathyroid 
destruction caused by thyroid surgery is a well documented cause of hypoparathyroidism. 
In contrast to an elevated PTH concentration, hypoparathyroidism is not a common 
finding in the elderly. SHPT due to chronic kidney disease and PHPT are important causes 
of hyperparathyroidism. Thus, progressing renal dysfunction and the development of 
hypercalcaemia in PHPT are thought to be closely involved in mediating the health 
outcomes of elevated PTH in these patients. However, elevated PTH levels are even more 
common in normocalcaemic older patients with a relatively well preserved renal function. 
Thus, vitamin D deficiency seems to be the most common cause of elevated PTH 
concentrations in the elderly. 
Hyperparathyroidism, namely SHPT due to chronic kidney disease and PHPT in 
particular, has been associated with several adverse health outcomes, including 
osteoporotic fractures, all cause mortality as well as cognitive dysfunction. Typically, the 
PTH concentrations have been very high or accompanied by hypercalcaemia or uraemia in 
these patients. However, the prognostic significance of subtle hyperparathyroidism has 
been less well established.  
This thesis addresses the predictive value of parathyroid hormone concentrations in 
older persons. This thesis also aims at investigating the factors confounding the responses 
of parathyroid hormone to vitamin D supplementation.  
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2. REVIEW OF THE LITERATURE 
2.1 Parathyroid hormone physiology 
There are usually four parathyroid glands that are typically located on the posterior surface 
of the left and right lobes of the thyroid, weighing approximately 500 mg together. The 
chief cells of the parathyroid glands are highly specialized to synthesize, process, and 
secrete the 84 amino acid PTH, i.e. intact PTH or PTH (1-84).  
2.1.1 Classical regulation of circulating parathyroid hormone 
The primary function of PTH is to maintain the calcium concentration of the extracellular 
fluid within a narrow normal range. PTH acts directly on bone and kidney and indirectly 
on the intestine through its effects in promoting the renal synthesis of calcitriol to increase 
serum calcium concentrations (Figure 1). The synthesis and secretion of PTH and the 
subsequent serum levels are tightly regulated by a negative feed-back loop. Serum ionized 
calcium (Ca2+), acting through the calcium-sensing receptor (CaSR), and vitamin D, acting 
through its nuclear receptor (VDR), inhibit PTH synthesis and release (Theman & Collins 
2009, Lehmann & Meurer 2010). Parathyroid synthesizes and secretes PTH unless it is 
restrained by CaSRs, whereas the binding of the vitamin D-VDR complex to the upstream 
regulatory element of the PTH gene decreases the rate of PTH gene transcription and 
parathyroid cell proliferation (Nagpal et al. 2005, Naveh-Many 2010). Serum P has also 
been recognized as an important regulator of circulating parathyroid hormone levels. An 
increase in P levels leads to increased PTH secretion, PTH mRNA stability, and 
parathyroid cell proliferation, similarly to low calcium (Naveh-Many 2010). 
Both the rate and magnitude of changes in the Ca2+ concentration are detected by 
extracellular CaSRs expressed on parathyroid cells. The CaSR is a member of family C G-
protein-coupled receptors and bears both structural homology and some degree of ligand 
crossover with the metabotropic glutamate receptors and γ-aminobutyric acid receptors 
(Theman & Collins 2009). CaSRs are also expressed in target tissues for PTH, in addition 
to chief cells of the parathyroid glands (Su et al. 2004). These target tissues of PTH 
regulate Ca2+ by translocating calcium ions into or out of the bodily fluids, and include the 
kidney, which expresses the CaSR at robust levels in certain nephron segments, and bone 
and intestine, which express the receptor at lower levels. 
Once secreted, PTH circulates freely in plasma and is rapidly metabolized in the liver 
and kidneys, the half-life being approximately four minutes. The parathyroid glands 
usually only contain enough PTH to maintain an increased stimulatory response for 
several hours. However, the synthesis of new PTH is also enhanced by hypocalcaemia, in 
addition to secretion, also ensuring the long-term requirements of increased parathyroid 
activity (Barret & Barret 2009). Furthermore, the rate of clearance of the secreted 84- 
amino-acid peptide from blood is more rapid than the rate of clearance of the fragments 
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corresponding to the middle and carboxyl-terminal regions of PTH (Figure 2), which have 
been considered biologically inactive (Murray et al. 2005). 
 
Figure 1 Control of mineral metabolism by parathyroid hormone (Shoback 2008).      
Copyright © [2008], Massachusetts Medical Society. All rights reserved. 
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Figure 2 Secretion, metabolism, and clearance of PTH. Drawn according to Endres et al. 
Copyright © [1989], Elsevier. All rights reserved 
2.1.2 Novel parathyroid-endocrine axis  
Recent discoveries have revealed that PTH mRNA stability is regulated by the balanced 
interactions of protective and the decay-promoting proteins (Naveh-Many 2010). The key 
regulator of these interactions has been identified as the peptidyl-prolyl cis/trans isomerase 
Pin1 (Figure 3). It has also been shown that Pin1 knockout mice have increased 
parathyroid gland PTH levels and circulating serum PTH concentrations without changes 
in serum calcium or P levels (Nechama et al. 2009). However, human studies are lacking. 
Fibroblast growth factor 23 (FGF-23) is also a newly identified bone-derived hormone 
that decreases PTH gene expression and secretion (Ben-Dov et al. 2007). In addition to the 
inhibition of expression of the renal sodium phosphate transporter, FGF-23 reduces renal 
1-alpha-hydroxylase expression leading to impaired production of 1.25-OHD, stimulates 
24-hydroxylase expression causing accelerated elimination of vitamin D, and decreases 
both PTH mRNA expression and PTH secretion from the parathyroid gland (Razzaque 
2009). FGF-23 signalling is also supported by an enhancing co-factor, klotho, a membrane 
protein involved in the renal regulation of calcium absorption (Razzaque 2009).  
 
CIRCULATION 
1 84 COOH 1         ? ?          84H2N COOH
Pre Pro PTH 
Pro PTH 
Parathyroid Gland 
PTH Carboxyl Fragments 
Hepatic metabolism 
Renal metabolism and 
clearance 
Carboxyl Fragments 
H2N 
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Figure 3 Novel regulators of PTH gene expression, secretion, and parathyroid cell 
proliferation (Naveh-Many 2010). Copyright © [2010], The Endocrine Society. All 
rights reserved.   
2.1.3 Actions of parathyroid hormone 
PTH is a true hormone, because it is produced by a gland and then travels through the 
bloodstream and binds to its receptor to act on its target tissues. It has been commonly 
held that all of the major biological activities of PTH are mediated by the N-terminal 
hormone residues within the (1–34) region. The classical actions of PTH on bone and 
kidney are aimed at the preservation of the calcium concentration and elimination of 
phosphorus.   
2.1.3.1 Classical actions on bone and kidney 
PTH binds to the parathyroid hormone receptor 1 (PTH1R), which has a high affinity for 
the N-terminal hormone residues within the (1–34) region of PTH. Synthetic PTH 
including the first 34 N-terminal residues, i.e. PTH(1-34), has also been shown to have a 
high affinity for PTH1R and the capacity to reproduce all the major effects of intact PTH, 
aiming at the maintenance of calcium homeostasis (Murray et al. 2005). PTH1R is a 
member of the class II family of G protein-coupled receptors (GPCR). Like other 
members of this family (including secretin, calcitonin, vasoactive intestinal peptide, 
glucagon-like peptide-1, growth hormone-releasing hormone, corticotropin-releasing 
factor, and glucagon receptor), it is capable of coupling to several different G proteins, 
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thereby concurrently activating multiple signalling pathways, including adenylyl 
cyclase/cAMP, phospholipase C (PLC), cytoplasmic Ca2+ and protein kinase C, when 
expressed in heterologous cell systems (Abou-Samra et al. 1992,  Bringhurst et al. 1993,  
Segre 1993,  Pines et al. 1994, Pines et al. 1996, Smith et al. 1996, Mannstadt et al. 1999).  
In addition to vitamin D and calcitonin, PTH acts as a major regulator of calcium 
homeostasis. In bone, the effects of PTH are complex and lead to the stimulation of bone 
resorption, which delivers calcium and P into the circulation. According to the prevailing 
view, persistently elevated PTH acts indirectly on bone resorption via PTH1Rs expressed 
on osteoblasts and stromal cells, causing an increased production of cytokines and reduced 
production of the antiresorptive protein, osteoprotegerin (Murray et al. 2005). This further 
leads to the differentiation of osteoclast precursors and to stimulation of the resorbing 
activity of mature differentiated osteoclasts. In contrast to the effects of persistently 
elevated PTH on bone health, intermittently elevated PTH has been shown to result in the 
increased formation of trabecular bone (Neer et al. 2001, Lotinun et al. 2002).   
PTH has three major actions in the kidneys. In the distal part of the nephron, PTH 
stimulates active Ca2+ reabsorption. The transient receptor potential vanilloid 5 (TRPV5) 
channel constitutes the luminal gate for Ca2+ entry in the distal convoluted tubule. PTH 
activates the adenylyl cyclase-cAMP-protein kinase A signalling cascade, which rapidly 
phosphorylates threonine-709 of TRPV5, increasing the  open probability of the channel 
and promoting Ca2+ reabsorption in the distal nephron (de Groot et al. 2009). The 
excretion of P is also enhanced by PTH in concert with fibroblast growth factor 23 
(Schiavi 2006), through the inhibition of renal type II sodium-phosphate cotransporter 
activity, leading to phosphaturia (Fukumoto et al. 2002). The third renal action of PTH is 
to promote vitamin D 1-hydroxylase responsible for 25-OHD hydroxylation to 1.25-OHD 
(Loré & Di Cairano 1986). 
Thus, when hypocalcaemia or hyperphosphataemia threatens to develop, these steps 
are able to restore the ionized Ca2+ levels to the physiological limits, and through the 
actions of PTH and other factors in the kidney, reset the level of serum P within the 
normal range. Finally, the increasing circulating Ca2+ and decreasing P induce a negative 
feedback effect on PTH synthesis and secretion (Figures 1 and 3). During recent decades, 
the differences in the skeletal effects of continuously elevated PTH and intermittent 
treatment with PTH have been well established (Neer et al. 2001). Continuous elevation of 
PTH results in decreased bone mineral density and an increased risk of osteoporotic 
fractures, but intermittent treatment has a strong anabolic effect on bone. 
2.1.3.2 Nonclassical actions 
In addition to the classical actions of PTH on bone and kidney aimed at the preservation of 
calcium homeostasis, some evidence also suggests PTH actions in other organ systems, 
since PTH1Rs are expressed throughout the human tissues. In addition to bone and 
kidney, the PTH1Rs have at least been identified in human heart, skeletal muscle and 
several regions of the brain (Reppe et al. 2007, Monego et al. 2009, Lupp et al. 2010), 
indicating possible actions of PTH in these tissues.  
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Experimental animal models of placebo-controlled PTH treatment have shown direct 
cardiovascular effects of parathyroid hormone, including myocardial damage (Bogin et al. 
1981), a prosclerotic effect on vascular smooth muscle cells (Perkovic et al. 2003), and 
accelerated decompensation following left ventricular hypertrophy (Cha et al. 2010). 
Thirdly, human studies of chronic (12 days) continuous intravenous PTH (1–34) infusion 
in healthy subjects (N = 4) have resulted in persistent hypercalcaemia and hypertension, 
reversible during a 4- to 8-day recovery period (Hulter et al. 1986). However, animal 
models have also associated PTH treatment with the inhibition of osteogenic vascular 
calcification (Shao et al. 2003), improved cardiac repair by enhanced neovascularization 
and cell survival after myocardial infarction (Zaruba et al. 2008), an improved mechanical 
response of cardiomyocytes to electrical stimulation (Tastan et al. 2009) and protective 
effects through the activation of bone marrow-derived stem cells, resulting in reduction of 
perfusion defects in experimental animal model of cardiac ischemia (Huber et al. 2010).  
It has also been reported that when high levels of PTH are sustained in rat hippocampal 
organotypic cultures, a toxic increase in intracellular calcium results (Hirasawa et al. 
2000). At 1 week of exposure, the toxic effects were dose-dependent over the range of 0.1 
pM to 0.1 microM, the minimum effective dose being 10 pM. Furthermore, the PTH (1 - 
34)-induced adverse effects were significantly inhibited by co-administration of Ca2+ 
channel blocker.  
Parathyroid hormone may also play a role in the maintenance of body composition. A 
prospective population-based study has associated higher PTH levels with decreased 
muscle mass and impaired muscle strength (Visser et al. 2003). Furthermore, PTH levels 
have been associated with increased body fat in the elderly (Pitroda et al. 2009). 
Parathyroid hormone receptor 2 (PTH2R) has also been characterized in humans. 
However, a tuberoinfundibular peptide of 39 residues (TIP39) instead of PTH has been 
found as the primary ligand for PTH2R. PTH2R and TIP39 constitute a neuromodulator 
system implicated in endocrine and nociceptive regulation (Bagó et al. 2009). Other 
receptors for PTH have also been characterised in other species, the importance of which 
to human physiology has remained uncertain (Murray et al. 2005).  
Carboxyl (C)-terminal PTH fragments have also been identified in the circulation in 
large amounts originating from direct secretion by the parathyroid glands as well as 
hepatic proteolysis of intact PTH. These fragments have been presumed to be biologically 
inactive, because they have no activity at the PTH1R, but compelling evidence suggests 
that the physiological parathyroid regulation of calcium and bone metabolism may 
additionally involve receptors for circulating C-terminal PTH ligands (Murray et al. 2005). 
There is no evidence to suggest that regions of PTH (1–84) located C-terminal to residue 
34 contribute to ligand binding or activation of the PTH1R. On the other hand, large 
portions of the C terminus of PTH (1–84) are highly conserved across species. For 
example, the sequences PTH (53–61) and PTH (65–75) are 80% identical and otherwise 
differ only by conservative substitutions across mammalian species. This high degree of 
evolutionary conservation strongly suggests the possibility of an additional, independent 
biological function for this region of the PTH molecule (Divieti et al. 2005). Receptors 
specific for the C-terminal region of parathyroid hormone have also been identified in 
bone-derived cells (Divieti et al. 2005, Banerjee et al. 2006), but the clinical relevance of 
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these observations is largely unknown. However, accumulation of the C-terminal 
fragments of PTH has been associated with decreasing renal function in humans (Patel et 
al. 2010). Furthermore, in experimental animal models, the administration of C-terminal 
PTH(7–84) has been shown to act as an antagonist to the effects of intact PTH, 
independent of PTHR1 in both bone and kidney (Divieti et al. 2002, Langub et al. 2003, 
Nakajima et al. 2009). 
2.2 Vitamin D physiology  
Vitamin D is a group of fat-soluble prohormones, the two major forms of which are 
vitamin D3, i.e. cholecalciferol, and vitamin D2, i.e. ergocalciferol. Cholecalciferol is 
formed in the skin after exposure to sunlight. Vitamin D can be also obtained from 
nutrients and supplements, but the formation of cholecalciferol in the skin is the most 
important source of vitamin D. Ergocalciferol is obtained by irradiation of plants or plant 
materials or foods. Even though vitamin D is not produced by a gland, it travels through 
the bloodstream and binds to a receptor to act on its target tissues like a hormone.  
2.2.1 Synthesis and metabolism of vitamin D 
Photochemical synthesis of vitamin D3 occurs cutaneously, where pro-vitamin D3 (7-
dehydrocholesterol) is converted to pre-vitamin D3 in response to sunlight (ultraviolet B 
radiation 280–315 nm) exposure. Vitamin D3, obtained from the isomerization of pre-
vitamin D3 in the epidermal basal layers or intestinal absorption of natural and fortified 
foods and supplements, binds to vitamin D-binding protein (VDBP) in the bloodstream, 
and is transported to the liver (Figure 4) (Barret & Barret 2009). 
In the liver, vitamin D-25-hydroxylase metabolizes vitamin D3 and D2 to calcidiol 
(25-OHD), which is then transformed to calcitriol (1.25-OHD) by 1-alpha hydroxylase 
(1α-OHase) in the kidney under the stimulation of PTH. The 1-alpha hydroxylation of 
calcidiol to calcitriol is tightly regulated by PTH (Lehmann & Meurer 2010). Other 
regulators are calcium, P, calcitonin, fibroblast growth factor 23, and 1.25-OHD itself. 
Increases in serum Ca2+, P and 1.25-OHD levels downregulate renal 1α-OHase 
expression, resulting in the suppression of 1.25-OHD synthesis.  
Following hydroxylation in the kidneys, calcitriol is released into the circulation, and 
again by binding to the VDBP carrier protein in the plasma it is transported to various 
target organs (Figure 4). The circulatory levels of 1.25-OHD are also kept relatively stable 
in physiological and most pathological conditions, whereas the vitamin D stores are 
sensitively reflected by the 25-OHD concentration. Many extrarenal cells and tissues have 
been shown to express 1α-OHase, and thus under the influence of cytokines 25-OHD can 
also be hydroxylated to 1.25-OHD in the target tissues themselves (Lips 2006). This 
extrarenal 1.25-OHD production is important for the paracrine and autocrine regulation of 
cell differentiation and function (Peterlik & Cross 2005, Oudshoorn et al. 2009). It has 
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been also suggested that 25-OHD may have additional direct effects on target tissues 
(Lehmann & Meurer 2010).  
 
 
Figure 4 Synthesis and metabolism of vitamin D. UV-B = Ultraviolet B radiation, 25-OHase 
=Vitamin D-25-hydroxylase, 25(OH)D3 = calcidiol, 1α-OHase =  1-alpha 
hydroxylase, 1α25(OH)2D3 = calcitriol, 24-OHase = Vitamin D-24-hydroxylase,  
24,25(OH)2D3 and 1α24,25(OH)2D3 = less active metabolites, P = Phosphate,Ca2+ 
= Serum  ionized calcium (Deeb et al. 2007). Copyright © [2007], Macmillan 
Publishers Ltd. All rights reserved. 
The elimination of both 1.25-OHD and 25-OHD is regulated by the kidneys through 
the actions of the mitochondrial enzyme vitamin D-24-hydroxylase (24-OHase), encoded 
by the cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1) gene. 
Expression of the 24-OHase in the kidney is stimulated by 1.25-OHD, and 24-OHase 
converts 1.25-OHD and 25-OHD into less active metabolites, which are then excreted to 
urine. These feedback mechanisms play an important role in the protection against 
hypercalcaemia and hyperphosphataemia during vitamin D sufficiency (Christakos et al. 
2007).  
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2.2.2 Actions of vitamin D 
Calcitriol can enter the cell and bind to the VDR, and subsequently to a responsive gene. 
Vitamin D also has rapid non-genomic effects through a membrane receptor and second 
messengers (Lips 2006). 
Upon binding to calcitriol, the VDR is phosphorylated and recruits one of the three 9-
cis-retinoid X receptors. Regulation of gene expression is then dependent on the ability of 
these heterodimers to build co-regulatory protein complexes, including the steroid receptor 
coactivators and the VDR interacting protein. These complexes bind to specific genomic 
sequences in the promoter region named vitamin D response elements. The VDR not only 
directly upregulates gene transcription but also directly downregulates the transcription of 
several genes such as those encoding parathyroid hormone (Lehmann & Meurer 2010). 
Calcitriol can also activate a variety of non-genomic signal transduction systems 
including Ca2+ influx; release of Ca2+ from intracellular stores; modulation of adenylate 
cyclase, phospholipase C, and protein kinases C and D; as well as mitogenactivated 
protein and rapidly growing fibrosarcoma kinase pathways. These activities have been 
found in many cells, including keratinocytes, enterocytes (intestinal absorptive cells), 
muscle cells, osteoblasts, and chondrocytes. VDR seems to be necessary for some of these 
nongenomic transduction processes; however, another protein named 1-alpha-25-
dihydroxy-membrane associated rapid response steroid binding protein is also seemingly 
involved in these rapid nongenomic actions (Lehhmann & Meurer 2010).  
The well documented actions of vitamin D include the increased absorption of calcium 
from intestines and enhanced reabsorption of calcium in the kidneys. One of the main 
mechanisms for Ca2+ absorption is the transcellular (active) route, which involves the 
entry of Ca2+ into the cell via Ca2+ channels, diffusion of Ca2+ through the cytosol bound 
to calbindins and active extrusion of Ca2+ via a Ca2+ pump or a Na/Ca exchanger (Perez et 
al. 2008). The epithelial Ca channels are members of the transient receptor potential super 
family, and more precisely, the vanilloid subfamily (TRPV). The TRPV5 channel is the 
major isoform in the kidney, while the TRPV6 channel is highly expressed in the intestine. 
Interestingly, animal models have shown close regulation of TRPV6 expression by 
vitamin D. Both in VDR and in 1-alpha hydroxylase knockout mice, intestinal TRPV6 
expression is strongly reduced, which impairs intestinal Ca2+ absorption (Song et al. 2003, 
Hoenderop et al. 2004). Less is known about the precise mechanisms of renal actions, but 
vitamin D may also be involved in the regulation of TRPV5 expression (Renkema et al. 
2005). 
The musculoskeletal effects of vitamin D supplementation have mostly been studied 
during recent decades. It appears that vitamin D supplementation improves neuromuscular 
functions, such as balance and reaction time (Dhesi et al. 2004, Lips et al. 2010), but has 
no major impact on muscle strength. However, the improved neuromuscular functions are 
thought to lead to a decreased risk of falls and subsequent fractures. Two recent meta-
analyses by Bischoff-Ferrari et al. have shown that supplemental vitamin D at a dose of 
700-1000 IU per day reduces the risk of falling among older individuals by 19%, and a 
dose higher than 400 IU a day should reduce nonvertebral fractures by at least 20% in 
individuals aged 65 years or older (Bischoff-Ferrari et al. 2009a, Bischoff-Ferrari et al. 
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2009b). Thus, vitamin D has been classically considered as counteracting PTH in the 
regulation of calcium homeostasis and bone health.  
Vitamin D receptors are found in most tissues and vitamin D is involved in the 
regulation of over 200 genes (Holick 2007). In fact, vitamin D seems to have a role in 
several different and important physiological processes such as cell differentiation and 
immune function (Figure 4). In observational studies, vitamin D deficiency has also been 
associated with many chronic diseases, including osteoporosis, cancer, cardiovascular 
diseases, diabetes, and dementia. These observations have led to recommendations to 
increase the intake of vitamin D of specific patients groups at risk, such as the elderly, by 
supplementation or fortification of foods, in order to reach 25-OHD levels of at least 75-
100 nmol/l (Souberbielle et al. 2010), even though conflicting results are also emerging 
(Bolland et al. 2010). Furthermore, high-quality large-scale randomized controlled trials 
addressing these putative pleiotropic effects of vitamin D are lacking and many of the 
performed trials have so far shown negative results.  
2.3 Parathyroid disorders in old age and their prognostic 
significance 
Parathyroid disorders include hyper- and hypoparathyroidism. Hypoparathyroidism refers 
to insufficient production of PTH in order to maintain calcium balance. When the actions 
of PTH are reduced or lost, all subsequent steps in the maintenance of calcium 
homeostasis are impaired, resulting in hypocalcaemia, hyperphosphataemia, and 
hypercalciuria. Post-surgical tetany as a cause of death was already observed in the 19th 
century in thyroidectomy patients. The early research also focused on the prevention of 
these deaths and led to the discovery of the parathyroid glands and hormone at the 
beginning of the 20th century. 
Hyperparathyroidism is due to increased activity of the parathyroid glands, either from 
autonomous hypersecretion (primary or tertiary hyperparathyroidism) or from a secondary 
increase in PTH secretion in response to hypocalcaemia (secondary hyperparathyroidism). 
An uncontrolled and nonsuppressed increase in parathyroid activity leads to 
hypercalcaemia and hyperphosphataemia, in addition to increased secretion of calcium to 
urine. Hyperparathyroidism was first described in the 1930s, and during the 1980s the 
introduction of automated calcium measurements revealed the common mild PHPT in the 
elderly. Because of the large number of heterogeneous conditions associated with 
parathyroid function, this chapter focuses on the existing data on parathyroid disorders as 
an outcome indicator in older persons, particularly in terms of mortality and cognition.   
2.3.1 Hypoparathyroidism  
Hypoparathyroidism is a rare disease and refers to reduced or lacking activity of the 
parathyroid glands, resulting in insufficient production of parathyroid hormone to 
maintain calcium homeostasis (Potts 2001). Hypoparathyroidism is most commonly seen 
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as a complication of thyroid surgery (Shoback 2008). Other causes are divided between a 
range of hereditary and acquired diseases such as DiGeorge syndrome (Kobrynski & 
Sullivan 2007), autoimmunity, and increased function of the CaSRs by either activating 
mutations (Pollak et al. 1994) or stimulatory antibodies (Kifor et al. 2004). In Finland, in 
particular, hereditary autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED) is a common cause of hypoparathyroidism (Perheentupa 2002). 
The parathyroid secretory reserve is ample, so considerable damage must occur before 
hypoparathyroidism develops (Shoback 2008). It is estimated that one normal gland is 
sufficient for maintaining PTH levels and serum calcium homeostasis. Definitions of 
permanent postsurgical hypoparathyroidism vary, but the definition is generally accepted 
to be insufficient PTH to maintain normocalcaemia 6 months after surgery. 
Hypoparathyroidism is estimated to occur after approximately 0.5 to 6.6% of total 
thyroidectomies; the rates of this complication are even higher in some case series, 
whereas reported rates at endocrine surgical centres with high volumes are 0.9 to 1.6% 
(Thomusch et al. 2003, Zarnegar et al. 2003, Page & Strunski 2007, Asari et al. 2008). 
Hypoparathyroidism is found in approximately 4 out of 100 000 patients at the population 
level. Thus, hypoparathyroidism is far less common than hyperparathyroidism in the 
elderly. 
Acute hypoparathyroidism can cause hypocalcaemia with consequent paresthesias, 
muscle spasms, seizures, and even tetany and death. In contrast, chronic 
hypoparathyroidism generally causes hypocalcaemia so gradually that the only symptom 
may be visual impairment from cataracts caused by years of hypoparathyroidism (Marx 
2000). It is also well known that the hypoparathyroidism related to APECED requires 
careful treatment and monitoring (Perheentupa 2002). However, there are no available 
data from clinical trials to show whether the complications of mild chronic hypocalcaemia 
related to mild hypoparathyroidism are preventable with aggressive therapy, or whether 
these patients derive benefits from therapy. Furthermore, the long-term prognostic 
significance of chronic hypoparathyroidism has not been systematically studied. 
2.3.2 Primary hyperparathyroidism 
Primary hyperparathyroidism is caused by adenoma, hyperplasia or carcinoma of one or 
more of the four parathyroid glands. Parathyroid adenoma is the most common cause of 
PHPT, whereas parathyroid carcinoma is rare. In PHPT, the hyperplastic or adenomatous 
glands are not able to correctly sense the circulating calcium concentration, and the 
physiological negative feedback between serum calcium and PTH secretion is thus 
disrupted. This disruption results in autonomous hypersecretion of PTH, and worsening 
hypercalcaemia develops in the course of the disease. The classical signs and symptoms of 
primary hyperparathyroidism are mainly attributable to hypercalcaemia, 
hypophosphataemia, hypercalciuria and increased bone resorption, including such clinical 
manifestations as renal caliculi, overt bone disease, neuromuscular dysfunction, 
gastrointestinal complaints as well as neuropsychological dysfunction (Bilezikian et al. 
2002). Patients lacking these clinical manifestations are termed “asymptomatic” in the 
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older literature. This definition is now ambiguous or inappropriate. Due to frequent 
measurements of calcium and PTH, the screening and diagnostic awareness of PHPT has 
improved significantly during recent decades, and the newly diagnosed PHPT patients 
have been found to have more vague symptoms (weakness and easy fatigability in the 
absence of overt muscle weakness). Some patients also seem to be truly asymptomatic 
(Bilezikian et al. 2009).  
The detection of hypercalcaemia has been the corner stone in the diagnosis of primary 
hyperparathyroidism (Figure 5). The population-based sex-adjusted incidence of primary 
hyperparathyroidism in U.S. whites (Rochester, Minnesota) was 21.6 per 100 000 person 
years during a 9-year follow-up, with a two-fold higher incidence in females (28.4 per 
100 000 person years) compared with males (13.8 per 100 000 person years) (Wermers et 
al. 2006). The incidence increased with age, reaching a peak of 63.2 per 100 000 person 
years at ages 65–74 yr. Furthermore, the prevalence of PHPT requiring clinical attention 
has been shown to be approximately 3% in older females and less than 1% in older men in 
Helsinki, Finland (Sorva et al. 1992).  
All symptomatic patients are usually treated by parathyroidectomy. However, the 
guidelines for surgical treatment of asymptomatic primary hyperparathyroidism patients 
have been changing during the last 20 years (Table 1). Furthermore, the 
neuropsychological symptoms have been ruled out in the consensus statements as an 
indication for surgery in asymptomatic patients. However, at Helsinki University Central 
Hospital, rapid development (within 1–2 years) of neuropsychological symptoms in a 
patient with a biochemically confirmed PHPT is also considered as an indication for 
parathyroidectomy. Medical management of asymptomatic PHPT is a promising option 
for those who are not candidates for parathyroidectomy. Bisphosphonates and hormone 
replacement therapy provide skeletal protection in patients with PHPT (Sankaran et al. 
2010). Calcimimetics favourably alter serum calcium and PTH in PHPT, but do not 
significantly affect either bone turnover or BMD (Khan et al. 2009).  
 
Table 1. Guidelines for parathyroid surgery in asymptomatic primary 
hyperparathyroidism 
Criterion Consensus 
Statement 1990 
Bilezikian  
et al. 2002 
Bilezikian 
et al. 2009 
1. Extent of hypercalcaemia  > 0.25-0.4 mmol/l > 0.25 mmol/l > 0.25 mmol/l 
2. 24 hr urinary calcium  > 10 mmol/d > 10 mmol/d Not indicated 
3. Creatinine clearance  Reduced by 30% Reduced by 30% Below 60 ml/min 
4. Bonde mineral density Z-score < -2  
(at forearm) 
T-score < -2.5  
(at any site) 
T-score < -2.5  
(at any site or 
previous fracture) 
5. Age  < 50 years < 50 years < 50 years 
6. Cognitive symptoms Not indicated Not indicated Not indicated 
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Figure 5 Biochemical investigation of hypercalcaemia should result in the measurement of 
intact parathyroid hormone, with the initial classification into parathyroid or non-
parathyroid causes on the basis of the combination of concentrations of parathyroid 
hormone and calcium. Further tests might be needed to establish the precise cause of 
hypercalcaemia in some patients. FBHH = familial benign hypocalciuric 
hypercalcaemia.  
2.3.2.1 Primary hyperparathyroidism and survival 
Increased cardiovascular mortality in patients with severe and moderately severe 
PHPT has been well documented (Palmer et al. 1987, Ronni-Sivula 1985, Hedbäck et al. 
1991, Ljunghall et al. 1991). Classically, the increased mortality and morbidity has been 
associated with higher total calcium (CaT) levels (Wermers et al. 1998, Lundgren et al. 
2001, Nilsson et al. 2002), and the beneficial effects of parathyroidectomy have been 
thought to be causally related to decreasing CaT levels (Hedbäck & Odén 1998). Nilsson 
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et al. analyzed mortality over a 30-year period in 10 995 Swedish patients who underwent 
parathyroidectomy. Although an increased risk of cardiovascular mortality was observed 
in the overall cohort, this risk dissipated in those enrolled later in the study, when the 
patients had lower levels of serum CaT. Another Swedish study on 4461 patients operated 
for primary hyperparathyroidism reported that the decline in the death risk paralleled the 
decrease in the mean preoperative serum CaT level over time (Hedbäck & Odén 1998). 
Although hypercalcaemia has been associated with such powerful cardiovascular risk 
factors as carotid plaque thickness (Rubin et al. 2007) and vascular calcification, the exact 
mechanisms underlying the increased risk of death related to hypercalcaemia have 
remained unclear. Nevertheless, cohort studies have also demonstrated that in 
symptomatic patients, bone density improves and the fracture rate declines after 
parathyroidectomy. Cognitive function appears to improve. The incidence of kidney 
stones declines after surgery in patients who had kidney stones before surgery. 
Cardiovascular disease and premature death also appear to decrease after surgery in 
symptomatic subjects (Udelsman et al. 2009). Thus, almost all patients with biochemically 
confirmed symptomatic PHPT are referred for parathyroid surgery in clinical practice. 
However, even though the higher mortality rate declines with time from 
parathyroidectomy, it persists long after the surgical cure, suggesting that PHPT may 
cause enduring damage to the cardiovascular system (Hedbäck et al. 1991, Nilson et al. 
2002).  
Studies from the US also including asymptomatic patients have shown different results 
(Wermers et al. 1998). Wermers et al. followed all residents with primary 
hyperparathyroidism in Rochester, Minnesota, for 15 years. A total of 309 cases of 
primary hyperparathyroidism (CaT = 2.67 ± 0.10 mmol/l, age = 56 ± 17 years) without 
surgery were identified during study period. The survival of patients was better than 
expected for white Minnesota residents of a similar age and gender, but higher CaT levels 
emerged as an independent predictor of mortality in these patients. The authors concluded 
that overall survival was not adversely affected among unselected patients with mild 
PHPT in the community, although patients with more severe disease indicated by higher 
serum CaT levels may have an increased risk of death (Wermers et al. 1998). Furthermore, 
according to a population-based US study, the survival of PHPT patients was also 
comparable to age- and sex-matched controls after parathyroidectomy (Söreide et al. 
1997), not supporting the hypothesis of enduring damage of the cardiovascular system. 
However, researchers from Europe have shown an increased risk among mild to moderate 
PHPT patients who did not undergo parathyroidectomy (Palmer et al. 1987, Lundgren et 
al. 2001). Lundgren et al. followed 55 patients with similarly mild hypercalcaemia (CaT 
2.67 ± 0.07 mmol/l, mean age 51 years) to those investigated by Wermers et al. in a case-
control study for 25 years. In contrast to the findings of Wermers et al., mortality was 
higher than expected in patients younger than 70 years and cardiovascular diseases were 
over-represented causes of death. However, Lundgren et al. also showed that 
hypercalcaemia independently indicated an increased risk of cardiovascular death (HR = 
1.72, 95%Cis = 1.24–2.37) in these patients. The existing incongruent evidence from 
mortality data, in particular cardiovascular mortality, in mild PHPT patients has been 
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explained by the variation in disease severity between study regions and the absence of 
population studies of mortality in a genuine mild PHPT cohort (Silfverberg et al. 2009).  
Within the last decade, a large body of the PHPT literature has focused on the proper 
management of mild and asymptomatic disease (Eastell et al. 2009, Khan et al. 2009, 
Silverberg et al. 2009, Udelsman et al. 2009, Sankaran et al. 2010). However, population-
based long-term follow-up studies and large-scale randomized controlled trials addressing 
the prognostic significance of asymptomatic PHPT and the effects of active treatment of 
these patients are still lacking. Recently, Yu et al. studied for the first time a representative 
population-based sample of 1683 (69.1% female) patients identified with mild PHPT (CaT 
= 2.58 mmol/l, mean PTH = 99 ng/l) during 1997–2006 in Tayside, Scotland (Yu et al 
2009). The authors showed that mortality and morbidity were increased for patients with 
mild untreated PHPT (standardized mortality ratio (SMR)-all cause = 2.62, 95%CI 2.39–
2.86; SMR-cardiovascular = 2.68, 95%CIs 2.34–3.05). The increases were similar to more 
severe PHPT. Furthermore, patients with mild PHPT have a significantly increased risk of 
developing cardiovascular and cerebrovascular disease, renal dysfunction and fractures 
compared to the age- and sex-adjusted general population. It should also be noted that the 
severity or mildness of PHPT in the studies referred to above has been defined by the 
degree of hypercalcaemia. Similar survival analyses based on PTH levels in PHPT have 
not been reported. 
2.3.2.2 Primary hyperparathyroidism and cognitive functions 
Current data on the association between primary hyperparathyroidism and cognitive 
functions are even less clear. It is well known that classical primary hyperparathyroidism 
was characterized by prominent psychological and neurological manifestations. The 
elevated serum calcium and PTH concentrations closely related to advanced primary 
hyperparathyroidism clearly have the potential to produce neuropsychiatric symptoms, and 
case reports have also shown that these cognitive symptoms are dramatically improved 
after parathyroidectomy (Logullo et al. 1998, Papageorgiou et al. 2008). However, it 
remains uncertain to what extent neuropsychiatric symptoms are present in the mild form 
of primary hyperparathyroidism commonly seen today. Symptoms such as fatigue, 
lassitude, mood swings, irritability, anxiety, depression, difficulty concentrating, memory 
loss, and increased sleep requirements have been studied in the PHPT patient population 
in a variety of case-control, cohort, and case series studies, but the results have been 
inconsistent (Caron & Pasieka 2009). The observational nature, small sample sizes, the 
inclusion of subjects with advanced symptomatic hyperparathyroidism, a lack of 
appropriate control groups, and testing at short intervals after parathyroidectomy have 
limited the conclusions that can be drawn from these studies.  
According to a recent systematic review of all data on neuropsychological assessments 
in PHPT, the data collectively suggest that the neurobehavioral syndrome associated with 
PHPT is ambiguous, and the impact of parathyroidectomy on differential improvement in 
cognitive functioning has been inadequately examined and may be confounded by the 
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presence of depression (Coker et al. 2005). In fact, Coker et al. found only six studies in 
which cognitive function was measured with formal neuropsychological tests.  
Recently, Perrier et al. performed a prospective randomized controlled trial of 
parathyroidectomy vs. observation in asymptomatic patients (N = 18, CaT = 2.58 mmol/l, 
mean PTH = 122 ng/l) (Perrier et al. 2009). They used functional magnetic resonance 
imaging together with sleep assessment and comprehensive formal neuropsychological 
testing and found an association between sleep and brain function. Sleep seemed to be an 
indicator of brain activation in the anterior ginculate gyrus and precentral cortex. 
Subjective sleepiness also decreased in the surgically treated patients, whereas the 
observed control patients reported increased sleepiness, resulting in a statistically 
significant difference between groups. However, this significance disappeared (P = 0.090) 
at the six-month re-evaluation. Interestingly, subjective sleepiness was also associated 
with executive functions, the impairment of which has been related to early stages of 
Alzheimer’s disease (Dickerson et al. 2007). Pilot data have also suggested that that a 
decrease in regional blood flow in patients with primary hyperparathyroidism can be 
demonstrated with single photon emission computed tomography of the brain (Mjåland et 
al. 2003, Cermik et al. 2007), and this decrease also seems to normalize after 
parathyroidectomy (Mjåland et al. 2003). However, the results of studies using formal 
neuropsychological testing have remained inconsistent during recent years (Benge et al. 
2009).   
Cognition has a major impact on the quality of life. Thus, it is noteworthy that Pasieka 
et al. have recently demonstrated the long-term benefit of parathyroidectomy in primary 
HPT patients (Pasieka et al. 2009). In this prospective study, the pre-operative symptoms 
of patients decreased after parathyroidectomy and contributed to the improved quality of 
life at 10 years, when compared to controls undergoing thyroid surgery. The pre-operative 
CaT decreased from a mean of 2.76 mmol/l to 2.30 mmol/l during the ten-year follow-up, 
the respective figures being 107 and 35 for parathyroid hormone. The positive effect of 
parathyroidectomy on the quality of life is supported by three other studies with shorter 
follow-up periods (Pasieka et al. 2002, Sheldon et al. 2002, Quiros 2003). 
Although patients with mild PHPT clearly have neuropsychological complaints, 
available data remain incomplete on their precise nature and their reversibility with 
surgery. However, there are some data supporting a modest beneficial effect of 
parathyroidectomy on the quality of life and psychological functioning. Further efforts to 
define neuropsychological and cognitive deficits that are specific to PHPT are needed 
(Silverberg et al. 2009). 
2.3.3 Secondary hyperparathyroidism 
Secondary hyperparathyroidism is a heterogeneous group of medical conditions that 
leads to a secondary increase in parathyroid secretion of PTH in response to 
hypocalcaemia, the major causes being vitamin D deficiency and chronic kidney disease. 
In secondary hyperparathyroidism, the cause of parathyroid gland overactivity is outside 
the glands themselves, and parathyroid function is thought to normalize if the external 
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cause is treated. The prevalence of an elevated PTH concentration has varied between 
20% and 60% in different elderly populations (Jensen 1999, Harris et al. 2001, Giusti et al. 
2006, Saraiva et al. 2007, Papavasiliou et al. 2009). The most frequent single cause of 
secondary hyperparathyroidism seems to be vitamin D deficiency and/or low calcium 
intake (Saleh et al. 2006). Furthermore, vitamin D deficiency and chronic kidney disease 
have been two areas of major clinical and scientific interest during recent years. However, 
in most subjects with secondary hyperparathyroidism, the cause is probably a combination 
of several factors. 
2.3.3.1 Vitamin D deficiency 
Vitamin D deficiency has been found to be very common globally (Holick 2007, Lips 
2010). Depending on the cut-point of adequacy, the reported prevalence of vitamin D 
deficiency has varied widely. It has been suggested that a 25-OHD level of 50 nmol/l 
would be sufficient and levels below 25 nmol/l would be deficient for older adults 
(Mosekilde 2005). Levels of 25-OHD between 25 and 50 nmol/l would correspond to 
vitamin D insufficiency. However, the evidence is accumulating to support the elevation 
of target levels of 25-OHD to 75 nmol/l (Bischoff-Ferrari et al. 2009a, Bischoff-Ferrari et 
al. 2009b, Souberbielle et al. 2010). 
There has been growing interest in the putative pleiotropic effects of vitamin D during 
recent years, despite the lack of evidence on causality. Autier and Ganidini published a 
meta-analysis on the effect of vitamin D supplementation on total mortality in 2007 
(Autier & Gandini 2007). They identified 18 independent randomized controlled trials, 
including 57 311 participants, that had also assessed mortality. However, none of the trials 
had mortality as a primary endpoint. Nevertheless, vitamin D supplementation indicated a 
relative risk reduction of mortality from any cause by 7% (Hazard ratio (HR) = 0.93, 
95%CIs 0.87–0.99). Since the publication of this meta-analysis, several epidemiological 
studies (Dobnig et al. 2008, Melamed et al. 2008, Ginde et al. 2009, Kuroda et al. 2009, 
Zittermann et al. 2009, Pilz et al. 2009, Semba et al. 2009, Semba et al. 2010, Hutchinson 
et al. 2010, Annweiler et al. 2010a) and one intervention trial (LaCroix et al. 2009) have 
addressed the association between vitamin D deficiency and survival.  
In a prospective cohort study of patients (N = 3258, mean = 62 years, follow-up 7.7 
years) referred for angiography within the LURIC study, all-cause multivariable-adjusted 
mortality was significantly increased by 53% (HR = 1.53, 95%Cia 1.17-2.01) in patients 
with a 25-OHD level below 32.5 nmo/l (Dobnig et al. 2008). Melamed et al. (N = 13 331, 
mean age = 43 years) and Ginde et al. (N = 3408, age ≥ 65 years) also performed nested 
prospective cohort studies within NHANES III with follow-ups of 8.7 and 7.3 years, 
respectively (Melamed et al. 2008, Ginde et al. 2009). In line with Dobnig et al., both 
studies reported an increased risk of all-cause mortality among patients with a low 25-
OHD level (< 45 nmol/l for Melamed et al., < 50 nmol/l for Ginde et al.). The increase in 
the risk of all-cause mortality was also significant after multivariable adjustment in both 
studies, and emphasized (HRs 1.86 vs. 1.26) among the older patients studied by Ginde et 
al.  
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 Kuroda et al. have reported an even higher increase in all-cause mortality in a 
prospective 6.9-year observational study of 1232 postmenopausal volunteers (mean age = 
63.9 years) from Japan. The multivariable-adjusted hazard ratio for death was 2.17 
(95%CIs 1.27–3.72) in patients with 25-OHD level below 50 nmol/l when compared to 
patients with a 25-OHD concentration 50 nmol/l or greater. Furthermore, Pilz et al. 
reported a multivariable-adjusted hazard ratio of 1.97 (95%CIs 1.08–3.58) in a population-
based sample (N = 614, age = 50–75 years). Semba et al. also reported high multivariable-
adjusted hazard ratios for all-cause mortality in two prospective population-based studies 
of older community-dwelling US women (N = 714, age = 70–79, HR = 2.87, 95%CIs 
1.10–7.4) (Semba et al. 2009) and Italians (N = 1009, median age = 74 years, HR = 1.97, 
95%CIs 1.11–3.47) (Semba et al. 2010). However, both studies by Semba et al. compared 
the lowest 25-OHD quartile to the highest. Furthermore, the most recent work by 
Hutchinson et al. using a single cut-point of 50 nmol/l for the 25-OHD level again showed 
a more modest 32% increase in the risk of all-cause mortality (multivariable-adjusted HR 
= 1.32, 95%CIs 1.07–1.62) in a non-smoking sample (N = 4751, mean age = 60 years) of 
the longitudinal population-based Tromsø study focusing on lifestyle-related diseases. 
Interestingly, Annweiler et al. found that lower 25-OHD levels were also associated 
with increasing risk of short-term (within hospital stay) mortality in an acute geriatric 
setting (N = 399, mean age 85 years). This study recruited all the patients admitted to the 
geriatric acute care unit of Angers University Hospital, France, between January and 
October 2009 who were able to give their informed consent. Furthermore, Zittermann et 
al. showed in a prospective cohort study of end-stage heart failure patients (N = 510, mean 
age = 53 years) that the 1-year survival of patients is impaired in patients with low levels 
of 1.25-OHD. 
  However, only some of the studies reviewed above measured parathyroid hormone 
concentrations (Pilz et al. 2009, Zittermann et al. 2009, Semba et al. 2009, Semba et al. 
2010, Hutchinson et al. 2010). Only Pilz et al. and Semba et al. also adjusted the results 
for parathyroid hormone levels. Furthermore, Hutchinson et al. did not include PTH in 
their “fully adjusted” model because PTH was not measured in all patients (approximately 
50%), but when PTH was entered into the models the significance of 25-OHD as a 
mortality indicator was lost. However, this was most probably due to the collinearity 
between PTH and 25-OHD.  
To date, there has been just one large-scale randomized controlled vitamin D 
supplementation trial having all-cause mortality as a primary endpoint (LaCroix et al. 
2009). LaCroix et al. randomized 36 282 women aged 50–79 years from 40 US centres to 
400 IU of vitamin D3 with 1000 mg elemental calcium carbonate daily or placebo for 7 
years. They found an almost significant benefit of the supplementation in terms of all-
cause mortality (HR = 0.91, 95%CIs 0.83–1.01). The study had problems with a high 
dropout rate and intervention contamination. Furthermore, the dose of vitamin D 
supplementation was relatively low for older adults, perhaps resulting in the larger range 
of 95%CIs in patients aged 70 years or older (HR = 0.95, 95%CIs 0.80–1.12) compared to 
the younger patients (HR = 0.89 95%CIs 0.79–1.01). 
The suggested mechanisms for the causal association between vitamin D and mortality 
have included hypertension through the activation of the renin-angiotensin system (RAS) 
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(Zittermann et al. 2006) and atherosclerosis through immune dysfunction (Saggese et al. 
1989). 1.25-OHD is a negative endocrine regulator of the RAS (Li 2003), and experiments 
on VDR knockout mice have suggested that cardiac hypertrophy is a consequence of 
activation of both the systemic and cardiac RAS (Xiang et al. 2005). In addition, the 
immune system appears to be involved in the pathogenesis of atherosclerosis (Libby 
2002), and 1.25-OHD seems to have immunosuppressive effects, with a reduction in 
lymphocyte proliferation and the production of cytokines (Saggese et al. 1989). 
Studies evaluating the effect of 25-OHD concentrations on cognition have reported 
mixed results, in part depending on which tests were used to assess cognitive function as 
well as differences in sample sizes. Overall, it appears that cognitive function, as assessed 
by the MMSE, is not associated with 25-OHD concentrations. However, other instruments 
that assess executive functioning have associated better performance with higher 25-OHD 
concentrations. Most of the studies have also been limited by cross-sectional methodology 
and a single measurement of 25-OHD, which does not allow control for seasonal 
fluctuation (Barnard K & Colón-Emeric 2010).  
2.3.3.2 Chronic kidney disease 
Secondary hyperparathyroidism occurs in chronic kidney disease as an adaptive 
response to deteriorating renal function. A combination of factors contribute to the 
increase in parathyroid hormone that are additive as the glomerular filtration rate (GFR) 
decreases. Circulating 1.25-OHD begins to decrease in stage 2, and continues to fall as the 
renal mass decreases and renal 1α-hydroxylase enzyme is inhibited by 
hyperphosphataemia, hyperuricaemia, metabolic acidosis, and vitamin D deficiency. As 
GFR decreases below 60 ml/min/1.73m2, P is retained and stimulates synthesis and 
secretion of parathyroid hormone. Hypocalcaemia, the hallmark of renal failure at the 
beginning of the disease, develops as the GFR decreases below 50 mL/min/1.73m2, further 
stimulating the release of the hormone. As GFR decreases further, the half-life of intact 
parathyroid hormone (1–84) increases and C-terminal fragments of the hormone 
accumulate. A relative state of end-organ resistance to the hormone exists, but chronic 
elevation of it has major consequences, resulting in bone loss (particularly cortical bone), 
fractures, cardiovascular disease, and increased mortality (Fraser 2009). 
The impaired survival associated with progressive chronic kidney disease has been 
well documented (Weiner et al. 2004a, Weiner et al. 2004b, Tonelli et al. 2006, Chronic 
Kidney Disease Prognosis Consortium 2010). Tonelli et al. performed a meta-analysis of 
39 studies that followed a total of 1 371 990 participants. They reported that during a 
median follow-up ranging from 1 to 16 years, the unadjusted relative risk for mortality in 
participants (mean age from 34 to 79 years) with reduced kidney function compared with 
those without ranged from 0.94 to 5.0 and was significantly more than 1.0 in 93% of 
cohorts. Among the 16 studies that provided suitable data, the absolute risk for death 
increased exponentially with decreasing renal function. The prevalence and severity of 
chronic kidney disease has been shown to increase with age, but this increase may be 
exaggerated by the current use of estimated GFR in CKD classification (Abdelhafiz et al. 
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2010). In fact, nearly half of the consecutive oldest old patients (≥ 80 years, N = 138, 
mean GFR = 32 ml/min/1.73m2) referred to a nephrology centre were classified to suffer 
from stage 4 or higher CKD (El-Ghoul et al. 2010). However, in one-third of the patients 
the renal dysfunction was found to be nonprogressive and associated with a lower 
mortality rate than in those with progressive kidney dysfunction. Simple covariates (low 
proteinuria, lack of hypertension, low cardiovascular comorbidity) predicted 
nonprogression of CKD in these patients. 
There are several possibilities for the mechanisms by which CKD might mediate the 
increased risk of death. First, CKD often coexists with other cardiovascular risk factors, 
including dyslipidaemia, hypertension, smoking, and diabetes (Hannedouche et al. 1993). 
Second, patients with evidence of renal disease are less likely to receive proven 
efficacious therapies (Tonelli et al. 2001). Third, impaired kidney function may merely be 
a marker for the severity of a vascular disease, including atherosclerosis, that is not yet 
clinically evident (Abdelhafiz et al. 2010). Fourth, impaired kidney function is associated 
with markers of inflammation and other putative risk factors of cardiovascular events and 
subsequent death (Garg et al. 2001, Stenvinkel et al. 2002, Stuveling et al. 2004, Knight et 
al. 2004). Finally, vascular and soft-tissue calcification, including the rare but often fatal 
calcific uraemic arteriopathy, is strongly linked with frank elevations in serum calcium, P, 
and parathyroid hormone in the setting of chronic kidney failure (Kestenbaum & 
Belozeroff 2007).  
The association of the parameters of mineral metabolism with excess mortality seems 
to be U-shaped in patients with advanced chronic kidney disease. In a follow-up (median 
21 months) study of 7970 random haemodialysis patients from 11 European countries, 
both low and high levels of total CaT (< 2.10 and > 2.75 mmol/l), P (< 1.31 and > 1.78 
mmol/l), and parathyroid hormone (< 150 ng/l and > 300 ng/l) were associated with 
increased risk of all-cause mortality in a fully adjusted model (Floege et al. 2010). 
Furthermore, Floege et al. used a time-dependent model, which also evaluates any 
potential effects of updating exposure and selected covariates over time. The U-shaped 
association has also been supported by a previous systematic review reporting a similar 
relationship between PTH and mortality (Kestenbaum & Belozeroff 2007). However, 
Floege et al. used two different methods for PTH analysis, which may result in 
misclassification of patients (Souberbielle et al. 2006), even though the updating of data 
over time reduces the possibility of such bias. Other limitations of the study by Floege et 
al include common missing data and a lack of 25-OHD measurements. 
Observational studies have also associated parathyroidectomy with improved survival 
of patients suffering from renal failure related secondary hyperparathyroidism (Costa-
Hong et al 2007, Dussol et al. 2007, Trombetti et al. 2007, Kestenbaum et al. 2004). The 
median survival of dialysis patients (N = 9116) was over six months longer during a 
median follow-up of 3 years in patients undergoing first parathyroidectomy compared to 
individually matched control patients who did not undergo parathyroidectomy 
(Kestenbaum et al. 2004). 
Cross-sectional studies have also suggested that impaired kidney function is associated 
with cognitive impairment in the elderly (Hailpern et al. 2007, Kurella Tamura et al. 2008, 
Barzilay et al. 2008) However, there have been few longitudinal studies examining the 
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association of impaired kidney function with the course of cognitive decline, and results 
from studies that have been reported are conflicting (Kurella et al. 2005, Slinin et al. 
2008). Recently, in a cohort of more than 850 community-dwelling older adults without 
dementia (GFR = 59.0 ± 15.8 ml/min/1.73 m2, MMSE = 27.9 ± 2.1), a decreased level of 
GFR or the presence of impaired kidney function at baseline was associated with a more 
rapid rate of cognitive decline (Buchman et al. 2009). This association between impaired 
kidney function and cognitive decline persisted after excluding participants with severely 
impaired renal function. The association of kidney function and cognition persisted even 
after controlling for several potential confounders such as BMI, serum haemoglobin, 
physical activity, social activity, vascular risk factors, vascular diseases, and depressive 
symptoms. Further analyses showed that kidney function was related to specific cognitive 
abilities, including episodic memory, semantic memory, and working memory, but not 
perceptual speed or visuospatial abilities. The systemic microvascular disease involving 
both renal and cerebral vasculature has been proposed as a potential mechanism of 
cognitive impairment in patients with chronic kidney disease (Murray 2008), but further 
studies are needed to determine the detailed biological basis for the association of kidney 
function and cognition. 
2.4 Parathyroid hormone as an outcome indicator in old age 
The prognostic significance of the parathyroid hormone concentration has been 
extensively studied in patients suffering from PHPT or SHPT due to renal failure. 
However, the significance of the parathyroid hormone concentration as an independent 
outcome indicator has been less well investigated. The following chapter focuses on 
studies that have addressed the association of PTH with mortality and cognition in other 
populations than selected hypercalcaemic PHPT patients or SHPT patients due to chronic 
kidney disease. Furthermore, studies published simultaneously with the present research 
are reviewed in the discussion.  
2.4.1 Mortality 
The predictive value of elevated PTH levels for increased mortality has been addressed in 
prospective studies in critically ill emergency room patients (Carlstedt et al. 1997, 
Carlstedt et al. 1998), in operatively treated hip fracture patients (Fischer et al. 2007) and 
in nursing home residents (Sambrook et al. 2004, Chen et al. 2008)  
The predictive role of PTH was first reported by Carlstedt et al. in 1997. The authors 
investigated the occurrence of hypocalcaemia and elevated PTH levels and their 
relationship with mortality and the severity of disease in a broad spectrum of 140 acutely 
ill patients suffering from common diseases such as stroke, acute abdominal disorders, 
obstructive lung diseases, heart failure, acute myocardial infarction, angina pectoris, 
trauma and infectious diseases (Carlstedt et al 1997). PTH was significantly elevated in 
non-survivors compared with survivors, and was found to be a stronger predictor of 
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mortality than the severity of disease score. In accordance with the early results of 
Carlstedt et al. in 238 consecutive older operatively treated hip fracture patients (mean age 
81.9 ± 7.8 years; 72% women), an elevated serum PTH level also emerged as a strong 
predictor of in-hospital all-cause mortality (HR = 18.5; 95% CI 2.0–72.3; p = 0.010) 
independently of age, sex, the 25-OHD level, and comorbidities (Fisher et al. 2007). 
However, the calcium concentration was not included in the multivariate model, even 
though the patients with higher PTH also had slightly higher levels of albumin-adjusted 
calcium (2.29 vs. 2.24 mmol/l, p = 0.001). Nevertheless, PTH levels also predicted peri-
operative myocardial injury indicated by TnI elevation above 0.006 µg/l in the study by 
Fisher et al. (2007). 
The predictive value of elevated PTH levels for impaired survival extends beyond the 
short follow-up of studies performed by Carlsted et al. (1997) and Fisher et al. (2007). 
This was shown during a mean follow-up of 31 months in a cohort study of older people 
(N = 842, mean age 85 years) living in residential care facilities (Sambrook et al. 2004). 
Furthermore, in this study PTH, but not 25-OHD, remained a significant predictor of 
mortality in the multivariate analyses corrected for health status, nutritional status, and 
renal function or bone ultrasound attenuation, in addition to serum calcium and P. In an 
extended follow-up study on the same study population, the absence of secondary 
hyperparathyroidism in the presence of hypovitaminosis D was common in the frail 
elderly and was associated with longer survival, similar to that observed in vitamin D-
replete elderly subjects (Chen et al. 2008). Their sample included 1280 older men and 
women. The prevalence of hypovitaminosis D (25OHD < 39 nmol/l) and absence of 
secondary hyperparathyroidism (PTH > 64 ng/l) in the presence of hypovitaminosis D was 
77.5% and 53.3%, respectively.  
Taken together, these epidemiological studies indicate an increased risk of mortality in 
selected patients with elevated serum PTH levels. The association seems to be 
independent of serum calcium levels, renal function and vitamin D status, and also appears 
to apply in older patients with different medical backgrounds.  
2.4.2 Cognitive functions 
The literature on the independent association between PTH and cognitive functions 
outside PHPT and renal failure patients is scarce. To date, there have only been three 
cross-sectional studies partly addressing this issue (Jorde et al. 2006, Hoogendijk et al. 
2008, Braverman et al. 2009). 
Jorde et al. investigated 21 normocalcaemic SHPT patients without renal failure (CaT 
< 2.40 mmol/L, serum PTH > 58 ng/l, and normal serum creatinine) and compared them 
with 63 control subjects using tests for cognitive and emotional function (Jorde et al. 
2006). Those in the SHPT group had significantly impaired performance in 3 of 14 
cognitive tests (Digit span forward, Stroop test part 1 and 2, and Word association test) as 
compared with the controls, and also had a significantly higher Beck Depression Inventory 
score. In a multiple linear regression model, a high serum PTH level was significantly 
associated with low performance in the Digit span forward, Stroop test part 1 and 2, and 
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Digit Symbol tests. A low level of serum 25-OHD was significantly associated with a high 
depression score. 
Since depressed mood is a well-known confounder of cognitive functions, it is 
worthwhile to also present the data from another large population-based cross-sectional 
study of older persons (1282 community residents aged 65 to 95 years) reporting a 
significant association between depression status and severity with decreased serum 25-
OHD levels (P = 0.03) and increased serum PTH levels (P = 0.008) (Hoogendijk et al. 
2008). Furthermore, some evidence also suggests that parathyroidectomy alleviates 
cognitive symptoms independently of changes in calcium levels or renal function in 
patients suffering from PHPT or SHPT due to renal failure (Chou et al. 2008, Burney et al. 
1999), supporting the independent role of PTH. However, the current data are scarce and 
lack consistency. 
Considering the fact that there are receptors for PTH and 1,25-dihydroxyvitamin D in 
the brain, and that there are clinical and experimental data indicating that PTH and vitamin 
D may affect cerebral function, future studies will be important in this field. 
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3. AIMS OF THE STUDY 
 
The studies presented in this thesis aimed at evaluating PTH as an outcome indicator in 
older people. The specific aims of the studies were:   
(1) To investigate the relationship between PTH and serum 25-OHD levels. 
(2) To evaluate the factors affecting the PTH response to vitamin D 
 supplementation. 
(3) To explore the prognostic significance of serum PTH levels in older adults 
 during the last years of life. 
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4. MATERIALS AND METHODS 
This thesis is based on six original publications: one meta-analysis of previous clinical 
trials (I), one cross-sectional study (II), one clinical vitamin D supplementation trial (III), 
and three prospective follow-up studies (IV-VI). The aims, study type, sample size, 
inclusion criteria, and primary endpoints of each study are shown in Table 2. 
 
Table 2. Summary of original publications
 Aims Study type N Inclusion criteria End points 
Study 
I 
Relationship 
between PTH 
and vitamin D 
Meta-
analysis 6290 
All clinical trials 
published until 
February 2007 
Correlation 
and 
associating 
factors 
Study 
II 
Relationship 
between PTH 
and vitamin D 
Cross-
sectional 
analysis 
218 
Long-term inpatients 
in Helsinki; age ≥ 65 
years, chronic 
immobility; stable 
general condition; no 
medication affecting 
calcium homeostasis 
Correlation 
and 
associating 
factors 
Study 
III 
PTH response 
to vitamin D 
supplementation 
Clinical trial 218 
Long-term inpatients 
in Helsinki; age ≥ 65 
years; chronic 
immobility; stable 
general condition; no 
medication affecting 
calcium homeostasis 
Changes in 
PTH 
concentration 
Study 
IV 
Independent 
prognostic 
significance of 
PTH 
Prospective 
follow-up of 
a population-
based cohort 
567 
Complete data on 
PTH and mortality at 
baseline 
All-cause 
mortality 
Study 
V 
Independent 
prognostic 
significance of 
PTH 
Prospective 
follow-up 218 
Long-term inpatients 
in Helsinki; age ≥ 65 
years; chronic 
immobility; stable 
general condition; no 
medication affecting 
calcium homeostasis 
All-cause 
mortality 
Study 
VI 
Independent 
prognostic 
significance of 
PTH 
Prospective 
follow-up of 
a population-
based cohort 
514 
Complete data on 
PTH and cognition 
excluding very severe 
dementia at baseline 
Cognitive 
decline 
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4.1 Meta-analysis of data on the relationship between PTH and 
25-OHD 
The meta-analysis of the published vitamin D supplementation trials (Study I) was based 
on a PubMed search performed in February 2007. The primary search was limited to 
clinical or randomized controlled trials, and the terms “vitamin D” AND “parathyroid 
hormone” were used. The primary search included 519 articles. A total of 102 articles that 
addressed the effects of vitamin D2 or D3 supplementation were selected for closer 
review. Trials not reporting both pre- and post-trial PTH and 25-OHD levels or focusing 
on PHPT or SHPT due to renal failure were excluded. The detailed flow-chart for the trial 
selection is shown in Figure 3. Furthermore, 11 other articles were included in the meta-
analysis through the review of the reference lists.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Flowchart of article selection for the meta-analysis 
4.2 Subjects 
Two study populations consisted of the long-term care inpatients from municipal hospitals 
in Helsinki, Finland, participating in a vitamin D supplementation trial (Studies II, III, and 
V) and a follow-up of a random cohort of older people living in Helsinki (Studies IV and 
VI).  
The long-term inpatients (N = 1215) from four municipal hospitals in Helsinki, Finland, 
were screened between September and December 2005 to participate in a vitamin D 
Primary search 
(n = 519) 
Included trials: 
42 RCTs 
10 Clinical trails 
Vitamin D2/D3 
supplementation 
(n = 102) 
No or other than 
vitamin D2/D3 
supplementation 
(n = 417) 
Other articles 
(n = 11) 
Excluded trials (n = 61): 
25-OHD or PTH not determined 
Renal failure 
Additional intervention 
Renal Transplant 
Review 
Thyroidectomy 
Primary hyperparathyroidism 
Anticonvulsant therapy 
Supplementation period < 2 weeks 
Cirrhosis 
Previously reported data 
Insufficiently reported data 
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supplementation trial. The inclusion criteria were age over 65 years, chronically impaired 
mobility, and stable general condition. However, a large majority of the patients were 
excluded during screening because of their present or recent (1 year) medication affecting 
calcium metabolism (vitamin D supplements, antiepileptics, glucocorticoids, osteoporosis 
medication). After baseline laboratory analyses, patients with markedly elevated creatinine 
(> 125 µmol/l), hypercalcaemia (Ca2+ > 1.32 mmol/l), hypo- (thyrotropin > 5.3 mU/l) or 
hyperthyroidism (thyrotropin < 0.2 mU/l) were also excluded. The flow chart of the 
vitamin D supplementation trial is shown in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Flowchart of the vitamin D supplementation trial  
 
In the prospective follow-up study called the Helsinki Aging Study, a random sample 
of persons born in 1904 (N = 300), 1909 (N = 300), and 1914 (N = 300) was selected from 
the census register in Helsinki, Finland (Tilvis et al. 2004). The participants alive at entry 
(N = 795) were mailed a questionnaire including several items about illnesses, 
medications, functioning, mood, and attitudes towards life. A total of 144 persons refused 
Patients Screened 
N = 1215
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Fulfilled 
N = 336
Baseline Blood 
Samples Obtained 
N = 250
Patients Randomised 
N = 218
Blood samples not 
obtained, 7 
Refusal, 24 
Lack of informed 
consent, 55 
Group I 
Vitamin D 0 IU/d 
N = 68
Group II 
Vitamin D 400 IU/d 
N = 77
Group III 
Vitamin D 1200 IU/d 
N = 73 
Refusal despite 
initial consent, 3 
Death before 
intervention, 7 
Renal failure, 
hypercalcaemia, 
hypo- or hyper-
thyroidism, 22 
Blood samples 
Clinical assessments 
Completed 
N = 59 
Blood samples 
Clinical assessments  
Study Completed  
N = 60 
Blood samples 
Clinical assessments  
Study Completed 
N = 63 
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to answer. At entry, participants (N =651) were examined clinically by a nurse, general 
practitioner, neurologist, and cardiologist, and the patient records were collected. 
The characteristics of the three different study populations are shown in Table 3. The 
patients in long-term care were the oldest. The PTH levels were also highest and 25-OHD 
levels lowest in these patients. The youngest patients with the lowest PTH levels were 
found among the data collected for the meta-analysis. 
 
Table 3. Characteristics of patients by study population 
Variable 
Meta-analysis of 
clinical trials  
Long-term care 
inpatients  
General aged 
population  
Number 6290 218 567 
Age, years 71.5 ± 10.7 84.5 ± 7.5 80.4 ± 4.2 
Women, % NA 81.7 73.7 
Co-morbidity, % NA NA 74.3 
Severe dementia, % NA 74.5 1.5 
Chronic immobility, % 2.7 100.0 NA 
Body mass index, kg/m2 NA 22.5 ± 4.7 25.6 ± 4.2 
25-hydroxyvitamin D, nmol/l 49.5 ± 22.4 22.8 ± 10.0 NA 
25-OHD < 50 nmol/l, % 51.7 98.2 NA 
Parathyroid hormone, ng/l 43.8 ± 16.6 60.9 ± 35.7 54.4 ± 64.7 
Hyperparathyroidism*, % 17.3 23.4 32.6 
Ionised calcium, mmol/l NA 1.22 ± 0.39 1.26 ± 0.05 
Total calcium, mmol/l NA 2.32 ± 0.10 2.41 ± 0.11 
Creatinine μmol/l NA 60.9 ± 19.7 94.4 ± 20.5 
Glomerular filtration rate, 
ml/min/1.73m2 
NA 64.5 ± 26.3 48.2 ± 12.9 
Albumin, g/l NA 33.4 ± 3.3 37.5 ± 3.4 
* PTH > 55 ng/l in the general aged population and systematic review; PTH > 73 ng/l in bedridden 
older inpatients 
NA = data not available 
4.3 Interventions 
The average daily doses of cholecalciferol or ergocalciferol were 853 ± 814 IU and 3602 ± 
4366 IU, respectively, in the 72 vitamin D supplementation groups included in the meta-
analysis (Study I). The average daily calcium dose was 564 ± 503 mg. The length of 
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supplementation was described as the time interval between laboratory analyses, the 
shortest being three weeks and the longest three years. However, 71.5% of the patients 
were supplemented for six months. 
The eligible long-term care inpatients patients (N = 218) were randomized into three 
treatment groups (Study III) receiving cholecalciferol (Vigantol®, Merck KGaA, 
Darmstadt, Germany 20 000 IU/ml in Migliol® oil) in doses of 0 µg, 140 µg, or 420 µg 
(groups I, II, and III) every two weeks, corresponding to daily intakes of 0 IU, 400 IU, or 
1200 IU, respectively (Figure 6). All three groups received identical volumes (26 drops = 
0.84 ml) of the medication oil. Furthermore, the oil was swallowed entirely in the presence 
of the nurse and given with a small amount of food or drink, if necessary. Each bottle was 
individually coded to blind the patients and ward nurses of both the content and the group 
labels of the bottles. A daily calcium carbonate substitution of 500 mg was given to 
patients during the intervention in case of insufficient use of dairy products (N = 40). The 
duration of the intervention was six months. 
4.4 Data collection 
Table 4 provides a summary of the laboratory analyses, clinical assessments and mortality 
data collected from the 52 trials included in the meta-analysis, from the long-term care 
inpatients participating in the vitamin D supplementation trial, and from the general aged 
population. It should be noted that data from placebo or control groups were not included 
in the meta-analysis. 
 
Table 4. Summary of data collection 
 
Standard 
laboratory 
analyses 
Additional 
laboratory 
analyses 
Clinical 
assessments 
Follow-up 
data 
Mortality 
data 
Meta-
analysis PTH 25-OHD 
Age, 
Mobility 
PTH, 
25-OHD - 
Long-term 
care 
inpatients 
Creat, Ca2+, 
PTH, Alb 
25-OHD, 
PINP, ICTP 
BMI, GFR, 
cognition 
All data at 
six months 
two-year 
data 
General 
aged 
population 
Creat, Ca2+, 
PTH, Alb 
APOE4 
phenotyping 
BMI, GFR, 
cognition, 
co-morbidity
Cognition at 
one, five and 
ten years 
17-year data 
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4.4.1 Laboratory analyses 
Two different methods for PTH analyses were used in this series of studies. In the general 
aged population (Studies IV and VI), an immunoradiometric method (AllegroR Intact 
PTH kit, Nichols Institute, San Juan Capistrano, CA, USA) was used to determine serum 
PTH (Ratcliffe et al. 1989). All PTH analyses were performed simultaneously. The 
sensitivity of the assay was 5 ng/l, the intra-assay CV was 3.6% at 45 ng/l and 6.1% at 390 
ng/l, and the inter-assay CV was 7.9% at 22 ng/l and 7.7% at 273 ng/l. The reference 
range was 10–55 ng/l. In the long-term care in patients, the PTH concentrations were 
determined with a solid-phase, two-site chemiluminescent enzyme-labelled immunometric 
assay (IMMULITE 2000 Intact PTH). The intra-assay coefficient of variation (CV) (N = 
20) was 5.7% at 72 ng/l and 4.3% at 258 ng/l (Kao et al. 1992). The interassay CV (N = 
10) was 6.3% at 54 ng/l and 8.8% at 387 ng/l. It is well known that the method of 
determination has a significant impact on the observed PTH concentration, and the 
IMMULITE 2000 Intact PTH has been shown to yield approximately 30 to 40% higher 
values for the PTH concentration (Souberbielle et al. 2006). 
Serum total calcium (CaT) was determined by the method of Gindler (Gindler et al. 
1972) in an automatic analyser (Hitachi model 705, Naka Woeks, Hitachi Ltd, Katsuta 
Japan). The inter-assay CV was 1.4% (long-term serum control) and the intra-assay CV 
was 0.7% in a subject serum sample with CaT 1.27 mmol/l, and 1.1% in a sample with 
CaT 3.15 mmol/l. The reference range was 2.20–2.60 mmol/l. Ionized calcium (Ca2+) was 
measured with an ion-selective electrode at pH 7.40 (Bowers et al. 1986). The inter-assay 
CV was 1.7% at a Ca2+ level of 0.75 mmol/l and 0.8% at a Ca2+ level of 1.75 mmol/l 
(long-term aqueous controls). The intra-assay CV was 0.5% both in a subject serum with 
0.70 mmol/l Ca2+ and in one with 1.74 mmol/l Ca2+. The reference range was 1.17–1.29 
mmol/l. 
Additional analyses in the general aged population included apolipoprotein E (APOE) 
allele phenotyping, which was done according to Menzel, Kladetzky, and Assmann 
(Menzel et al. 1982) with some modifications (Enholm et al. 1986).  
Additional analyses in the long-term care patients included vitamin D status by 25-
OHD and bone turnover by amino-terminal propeptide of type I procollagen (PINP), 
carboxyl-terminal telopeptide of type I collagen (ICTP). High performance liquid 
chromatography was used to measure plasma 25-OHD levels (Turpeinen et al. 2003). The 
method’s limit of quantification, defined as the lowest concentration with a signal-to-noise 
ratio of 10:1, was 10 nmol/L. The within-assay CV was 5.6% at 21.6 nmol/l (N = 14) and 
3.7% at 138 nmol/l (N = 15). The total CV was 7.3% at 16.4 nmol/l (N = 12) and 5.7% at 
167 nmol/l (N = 15). Similar to PTH measurement, the observed concentration of 25-OHD 
also depends on the method used, but to a lesser extent (Carter 2010). However, the HPLC 
method used in the present study has been considered as one of the most reliable methods. 
Plasma ICTP levels were determined by radioimmunoassay (RIA) (Risteli et al. 1993). 
The method yielded CVs between 3 and 8% for a wide range of concentrations. The levels 
of PINP were also analysed using RIA (Melkko et al. 1996). The inter- and intra-assay 
CVs ranged from 3.1 to 9.3% (N = 191) for values within the reference intervals (mean ± 
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2SD) for intact PINP in serum, which ranged from 19 to 84 g/l for women and from 20 to 
76 g/l for men. 
 
4.4.2 Clinical assessments 
All clinical assessments of the long-term care inpatients were based on the Resident 
Assessment Instrument Minimum Data Set 2.0 assessments (Morris et al. 1990). 
Cognition of the patients was assessed using the cognitive performance scale (CPS) 
(Morris et al. 1994). The CPS is divided into seven categories of cognitive impairment (0 
= none, 1 = borderline, 2 = mild, 3 = moderate, 4 = moderate to severe, 5 = severe and 6 = 
very severe), and the scores closely correspond with those generated by the Mini-Mental 
State Examination (24.9, 21.9, 19.2, 15.4, 6.9, 5.1, and 0.4, respectively).   
Among the random age cohorts, all subjects (N = 567) were clinically examined and 
assessed for co-morbidity. Subjects were identified as healthy (no co-morbidity) if their 
subjective and objective (according to the examining physicians) health was good or 
moderate, they had no hypertension, diabetes, dementia, or symptoms of cardiovascular, 
cerebrovascular, or pulmonary diseases, cancer or other disabling diseases, and had a 
normal exercise tolerance in relation to their history. Complete assessment of cognition, 
including the Mini-Mental State Examination (MMSE) (Folstein et al. 1975) and Clinical 
Dementia Rating (CDR) (Hughes et al. 1982), was performed in 514 subjects at baseline. 
Cognitive impairment was defined as an MMSE score below 24 and CDR class one or 
higher. Patients with a baseline MMSE score below 4 and patients in the highest CDR 
class were excluded from follow-up analyses for cognitive decline in study II, because 
cognitive decline was defined as at least a 4-point decrease in the MMSE score or increase 
in the CDR class. Both CPS and MMSE are validated and widely accepted tools for the 
assessment of cognitive function in the elderly.  
The body mass index (BMI) and glomerular filtration rate (GFR) estimated by the 
Cockcroft-Gault equation (Levey et al. 2003) were also calculated in both study 
populations. 
4.4.3 Mortality data 
Two-year mortality data on the long-term care inpatients were collected from patient 
records in January 2008, whereas among the random age cohorts the date of death for each 
diseased subject was drawn from the National Census Records in July 2007. The 
collection was complete for the long-term care patients, but five subjects were excluded 
from the survival analysis among the random age cohorts, because the mortality data were 
not obtained due to an incomplete social security number.  
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4.5 Statistics 
The data were analysed using Windows SPSS (SPSS for Windows, Chicago: SPSS 
Inc.). All variables were examined for outliers, missing data, and entry error. Differences 
in proportions were tested with a chi-squared test, and continuous measurements with 
analysis of variance. The independent samples T-test was used to test the equality of 
means between the two populations.  
In the meta-analysis, linear and logarithmic curve estimation regression models for 
baseline and post-trial levels of PTH as well as for changes in PTH were produced. Series 
of multivariate linear regression models were also created, respectively, to determine the 
changes in R2 and their levels of significance by entering each of the potential 
determinants stepwise into the models. All variables were weighted by the number of 
patients in each intervention group 
For the follow-up studies, Kaplan-Meier analysis was used to determine the median 
survival times for patients with varying PTH levels. Series of Cox regression models were 
created in order to calculate the hazard ratios and their level of significance for the 
predictive value of PTH on survival. Series of multivariate logistic regression models were 
also created to calculate the risk ratios and their level of significance for the predictors of 
cognitive decline. Age and gender were used as standard covariates. Other confounders 
were retained in the model based upon their established association with the mortality rate. 
Covariates were entered one by one into the model. Logarithmic transformation of a 
variable was used in the calculation of P-values if the distribution was not normal. P-
values below 0.05 were considered statistically significant. 
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5. RESULTS 
5.1 Relationship between PTH and 25-OHD levels (Studies I-III) 
In the meta-analysis of the published clinical vitamin D supplementation trials (Study I), 
the relationship between PTH and 25-OHD levels and the factors affecting the effects of 
vitamin D supplementation on the PTH response were addressed. These issues were also 
investigated in a randomized controlled trial of 218 older chronically bedridden inpatients 
(Studies II and III). 
5.1.1 Cross-sectional observations 
A significant negative correlation was found between baseline PTH and 25-OHD levels (r 
= -0.593, p < 0.001) in the meta-analysis. This held also true when all pre- and post-trial 
values were scattered (Figure 8).  
  
 
Figure 8 Relationship between serum levels of 25-hydroxyvitamin D and parathyroid hormone 
in 72 intervention groups of 52 vitamin D supplementation trials (N = 6290) when all 
pre- and post-trial values were scattered. R-square for the linear correlation is 0.294 
(p < 0.001). Parathyroid hormone levels are means and the standard deviation is 
shown by error bars. 
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The correlation between baseline PTH and 25-OHD levels (r = −0.126, p = 0.064) was 
substantially weaker in the chronically immobile long-term care inpatients in Study III 
(Table 5). Furthermore, in Study II the PTH levels were elevated above the laboratory 
reference (72 ng/l) in 25% of the long-term care inpatients, despite widespread (99%) 
vitamin D deficiency. The proportion of low PTH levels, i.e. blunted PTH responses, was 
also higher in the long-term care patients than in the meta-analysis (Table 5). 
 
Table 5. Relationship between PTH and 25-OHD levels. 
 
Baseline 
Pearson’s 
correlation 
coefficient 
Post-trial 
Pearson’s 
correlation 
coefficient 
Prevalence of 
blunted PTH* 
Meta-analysis r = -0.593 p < 0.001 
r = -0.196 
p < 0.001 21.9% 
Long-term care 
inpatients 
r = -0.126 
p = 0.064 
r = -0.261 
p < 0.001 29.4% 
* Percentage of PTH < 40 ng/l in patients/intervention groups with 25-OHD < 50 nmol/l 
 
In fact, in addition to their chronic immobility, the long term-care inpatients were 
markedly older (84.5 ± 7.5 years, range 65.0–104.3 years) than the patients included in the 
meta-analysis (Table 3). In the multiple regression analyses, age and chronic immobility 
also emerged as independent predictors of the baseline PTH concentration (Table 6). 
 
Table 6. Multiple linear regression analyses of average pre- and post-trail parathyroid 
hormone levels and their changes in 72 treatment groups of 52 vitamin D 
supplementation trials (N = 6 290)
   Change statistics 
Added variable R-Square Adjusted R-Square 
R-Square 
change 
p-value 
for change 
Dependent variable: Pre-trial PTH* 
Age, years 0.389 0.389 0.037 <0.001 
Immobility 0.390 0.390 0.001 0.005 
Dependent variable: Post-trial PTH† 
Immobility 0.672 0.672 0.045 <0.001 
Age, years 0.706 0.706 0.034 <0.001 
Dependent variable: Changes in PTH‡ 
Immobility 0.531 0.531 0.031 <0.001 
Age, years 0.559 0.558 0.028 <0.001 
* Adjusted for pre-trial 25-OHD, immobility, and age. 
† Adjusted for post-trial 25-OHD, pre-trial PTH, immobility, and. 
‡ Adjusted for changes in 25-OHD, pre-trial PTH, immobility, and age. 
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Since low PTH levels, i.e. blunted PTH responses, were prevalent in the long-term care 
inpatients, the factors associating with the lowest PTH quartile (PTH < 38 ng/l) were 
further addressed (Study II). Patients with low PTH were characterised by a history of hip 
fracture, low BMI, higher bone resorption marker ICTP, and shorter length of stay. In the 
logistic multiple regression analysis, a history of hip fracture, BMI, and ICTP also 
emerged as independent associates of the lowest PTH quartile (Table 7). Blunted PTH also 
proved to be persistent over time. At six-month re-examination, a blunted PTH response 
was recorded in 59.3% (35/59) of the surviving patients. Closer analysis also revealed that 
in 32 (76.2%) of the 42 survivors with a blunted baseline PTH response, the PTH level 
remained within reference values even after 6 months, despite persistent vitamin D 
deficiency. SHPT developed in only eight patients (19.0%) with blunted PTH at baseline. 
Furthermore, all patients remained bedridden.  
 
Table 7. Independent associates of the lowest quartile of plasma intact parathyroid 
hormone (PTH) at baseline (N = 52)* 
Variable Odds Ratio 95% Confidence Intervals 
History of hip fracture 2.893 1.239 6.754 
Body mass index 0.910 0.841 0.984 
ICTP† 1.120 1.012 1.240 
* Length of stay, history of hip fracture, body mass index, and ICTP were entered. 
† Carboxy-terminal telopeptide of type I collagen. 
5.1.2 Responses of parathyroid activity to vitamin D supplementation 
A strong negative linear (r = -0.620, p < 0.001) correlation between the changes in 25-
OHD and PTH levels was found in the meta-analysis (Study I, Figure 9). Closer analysis 
revealed that PTH decreased consistently in most (63/72) of the intervention groups, the 
average decrease being 22.0 ± 15.7% in the responding groups. Again, the correlation 
between changes in PTH and 25-OHD was clearly weaker (r = −0.209, P = 0.005) in the 
chronically immobile older inpatients. Furthermore, in line with the cross-sectional 
observations, age and chronic immobility emerged as independent predictors of changes in 
PTH concentrations in the multiple regression analyses of the meta-analysis (Table 6). In 
fact, together with pre-trial PTH and changes in 25-OHD, age and chronic immobility 
explained 53.2% (R-square = 0.532) of the variation in the responses of PTH to vitamin D 
supplementation. Closer analysis also demonstrated that vitamin D supplementation 
resulted in a smaller decrease in PTH levels (-8.4% vs. -17.4%, p <0.001), despite a larger 
increase in 25-OHD levels (187.2% vs. 109.8%, p < 0.001), in the chronically immobile 
patients.  
However, despite the older age and chronic immobility of the long-term care 
inpatients, both the six-month 400 IU/d and 1200 IU/d vitamin D supplementations were 
able to modestly reduce the PTH concentration (Study III, Table 8). Furthermore, the ratio 
of PINP to ICTP decreased significantly (0.2% with placebo, -11.8% with 400 IU/d, 
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-19.0% with 1200 IU/d, P = 0.025), providing further evidence for decreased bone 
turnover. 
 
 
Figure 9 Correlations between changes in the levels of 25-hydroxyvitamin D and parathyroid 
hormone in 72 intervention groups of 52 vitamin D supplementation trials (N = 
6290). R-square for the linear correlation is 0.385 (p < 0.001). 
Table 8. Changes in biochemical variables after six months of vitamin D 
supplementation 
 Group 
 
P-value Variables mean ± SD 
I 
Placebo 
II 
400 IU/d 
III 
1200 IU/d 
25-hydroxyvitamin D nmol/l 1.9±10.2 26.5±11.8 49.1±19.5 0.000 
Parathyroid hormone ng/l 5.2±20.0 -4.2±20.1 -4.7±24.1 0.021 
ICTP* μg/l -0.60±2.48 -0.08±2.25 1.06±6.23 0.078 
PINP† μg/l -1.80±21.07 -7.51±24.86 -7.78±13.62 0.194 
Ratio of PINP to ICTP‡ 0.00±0.36 -0.14±0.50 -0.19±0.33 0.025 
Ionized calcium mmol/l/pH7.40 0.017±0.034 0.024±0.073 0.032±0.038 0.061 
* Carboxyl-terminal telopeptide of type I collagen (ICTP) 
† Amino-terminal propeptide of type I procollagen (PINP) 
‡ PINP / (7 x ICTP) 
 
 
 
 
51
5.2 Predictive value of an elevated PTH concentration 
The role of PTH as an outcome indicator was evaluated in both a general aged population 
(Studies IV and VI) and in long-term care inpatients (Study V).  
A large majority of the patients were women, and the mean age was above 80 years in 
both study populations (Table 3). Old age was associated with impaired renal function, 
lower serum albumin, and an increased prevalence of secondary hyperparathyroidism, in 
particular, in both study populations. Co-morbidity was found in 74.3% of patients in the 
general aged population, whereas all of the older inpatients were considered co-morbid. 
Cognitive function was relatively well preserved (MMSE ≥ 24) in most (60.5%) persons 
of the general aged population, and severe dementia (MMSE < 7) was found in only 1.5% 
of patients. However, up to 74.5% of the older inpatients suffered from severe cognitive 
impairment (CPS > 3; comparable with MMSE < 7), and none of the inpatients had 
preserved cognitive functions (CPS = 0; comparable with MMSE > 22) at baseline.  
The PTH concentrations ranged from 3 to 1394 ng/l and 12 ng/l to 268 ng/l in the 
general population and older inpatients, the cut-points for quartile IV being 63 ng/l, and 72 
ng/l, respectively. Hyperparathyroidism was found in 32.6% (PTH > 55 ng/l, laboratory 
reference value) of those in the general aged population, the respective figure being 25.2% 
(PTH > 73 ng/l, laboratory reference value) in the older inpatients. Age and renal function 
associated with PTH levels in both study populations (Tables 9 and 10). High PTH 
concentrations were also significantly associated with impaired cognitive function in the 
general population. Patients with PTH in quartile IV were also characterized by co-
morbidity and impaired renal function (both study populations), as well as a higher BMI 
(older inpatients). 
 
Table 9. Baseline characteristics of the general aged population by quartiles of PTH 
(cut-points for quartiles 33, 45, and 63 ng/l, respectively). 
Variables mean ± SD 
Quartile 
I 
Quartile 
II 
Quartile 
III 
Quartile 
IV 
P-value 
for 
Trend 
Number 134 151 140 142  
Age, years 79.0±3.9 80.0±4.3 80.5±3.9 82.0±4.0 <0.001 
Women, % 57.6 74.5 78.1 84.5 <0.001 
Co-morbidity, % 69.2 73.8 80.1 74.4 0.215 
Severe dementia, % 3.9 0.8 0.7 0.9 0.103 
MMSE 23.8±5.4 24.2±5.4 23.8±5.5 22.4±5.6 0.048 
Body mass index, kg/m2 26.1±4.0 25.4±3.9 25.8±4.1 25.0±5.0 0.270 
Ionised calcium, mmol/l 1.26±0.04 1.25±0.04 1.25±0.04 1.26±0.08 0.397 
Total calcium, mmol/l 2.40±0.08 2.39±0.08 2.39±0.10 2.42±0.14 0.217 
Phosphate, mmol/l 1.03±0.13 1.03±0.14 1.00±0.14 1.02±0.16 0.206 
Creatinine μmol/l 89.6±15.6 91.1±16.5 96.6±17.8 100.1±28.0 <0.001 
GFR, ml/min/1.73m2 52.4±12.3 49.0±12.6 47.7±12.2 43.5±13.2 <0.001 
Albumin, g/l 37.2±3.0 37.4±3.6 37.7±3.4 37.6±3.5 0.695 
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Table 10. Baseline characteristics of chronically immobile older inpatients by quartiles 
of PTH (cut-points for quartiles 38, 58, and 72 ng/l, respectively). 
Variables mean ± SD 
Quartile 
I 
Quartile 
II 
Quartile 
III 
Quartile 
IV 
P-value 
for 
Trend 
Number 52 54 57 55  
Age, years 84.1±7.5 82.9±6.9 83.7±7.7 87.4±7.0 0.007 
Women, % 78.8 79.6 82.5 85.5 0.807 
Severe dementia, % 71.2 75.9 75.0 75.9 0.934 
CPS 4.8±1.5 4.9±1.5 5.0±1.3 4.8±1.3 0.950 
History of hip fracture, % 25.0 9.3 12.3 9.1 0.056 
Body mass index, kg/m2 21.0±4.1 22.4±5.4 22.5±4.2 23.9±4.7 0.016 
25-OHD, nmol/l 24.3±8.8 23.7±10.2 22.1±10.7 21.2±10.2 0.374 
ICTP 9.3±4.6 8.2±2.7 7.1±2.8 7.5±2.4 0.003 
PINP 52.3±20.2 53.2±20.5 52.6±25.5 54.3±22.9 0.967 
Ionised calcium, mmol/l 1.23±0.04 1.22±0.04 1.23±0.04 1.22±0.04 0.587 
Total calcium, mmol/l 2.33±0.10 2.31±0.09 2.33±0.09 2.32±0.11 0.825 
Phosphate, mmol/l 1.03±0.13 1.04±0.13 0.98±0.15 0.98±0.12 0.018 
Creatinine μmol/l 57.8±17.6 57.8±18.8 58.7±20.9 69.0±19.3 0.005 
GFR, ml/min/1.73m2 61.7±20.5 71.5±27.9 70.9±31.5 53.8±19.2 0.001 
Albumin, g/l 33.4±3.3 32.9±3.0 33.6±3.6 33.6±3.5 0.641 
5.2.1 Survival prognosis 
Up to 93% of the random persons aged 75, 80, and 85 years at entry had died during the 
long 17-year follow-up. The mean follow-up time of the older bedridden inpatients was 
not more than 25.3 months (range 24.4–26.5 months). However, up to 56.9% of the 
inpatients died during the follow-up. 
Elevated serum PTH levels (IV quartile) were significantly associated with an 
impaired survival prognosis in both the general aged population and the older inpatients 
(Figures 10 and 11). In the general aged population, PTH levels above 63 ng/l predicted a 
1.51-fold (95% CI: 1.25–1.86) over-mortality, resulting in a 2.3-year shorter median life 
expectancy. The predictive value of elevated PTH (quartile IV) was very similar in the 
bedridden inpatients, with a 1.58-fold (95%CIs 1.08–2.32) over-mortality and a 9.1-month 
shortening of the median life expectancy. It should be noted, however, that the cut-point 
for quartile IV of the PTH concentration that was used to stratify patients for comparison 
was slightly higher in the older inpatients than in the general aged population (72 ng/l vs. 
63 ng/l).  
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Figure 10 Survival prognosis according to PTH quartiles in the general aged population. 
Median survival shown by lines for the first and fourth quartile. 
 
Figure 11 Survival prognosis according to PTH quartiles in bedridden older inpatient. Median 
survival shown by lines.  
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The predictive value of elevated PTH also remained significant after adjusting for 
confounders in both patient groups (Table 11). Closer analysis revealed that over-mortality 
was consistent in all subgroups with one exception (Figure 12). The prognostic 
significance of elevated PTH for impaired survival was not observed in a subgroup of the 
older inpatients with preserved renal function. However, after controlling for GFR alone, 
the predictive value of elevated PTH also remained marginally significant (HR = 1.47, 
95%CIs 0.99-2.17, p = 0.055) in the older inpatients. 
 
Table 11. Predictive value of elevated parathyroid hormone in the aged general 
population and chronically bedridden older inpatients. 
 Hazard Ratio 95% Confidence Interval 
17-year follow-up of the general aged population (PTH ≥ 63 ng/l) 
Uncontrolled 1.56 1.29–1.88 
Controlled for 1.24 1.01–1.53 
Two-year follow-up of chronically bedridden older inpatients (PTH ≥ 72 ng/l) 
Uncontrolled 1.58 1.08–2.32 
Controlled for 
†
1.60 1.06–2.42 
* Adjusted for age, gender, co-morbidity, ionized calcium, and creatinine. 
† Adjusted for age, gender, BMI, creatinine, 25-OHD, six-month vitamin D 
supplementation group, ionized calcium, and albumin. 
 
 
Figure 12 The hazard ratios (95% confidence intervals by T-bars) for the predictive 
value of elevated PTH (≥ 63 ng/l) in relation to mortality by age cohort, 
gender, the presence of co-morbidity, the median of the estimated glomerular 
filtration rate (eGFR), and ionized calcium (Ca2+). 
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5.2.2 Cognitive decline 
The predictive value of PTH for cognitive decline was evaluated in the general aged 
population alone, because the oldest inpatients were already severely demented at 
baseline. 
Cognitive decline was assessed three times during the 10-year follow-up in the general 
aged population. Cognitive decline (MMSE-score decrease ≥ 4 points) was found in 
15.5% of these subjects within the first year of follow-up, when cognition was assessed 
with the MMSE. The respective figure was 31.1% for an increase in the CDR class. 
Elevated PTH indicated a 2-fold higher risk for at least a 4-point decrease in the MMSE 
and a 3-fold risk for increase in the CDR class within the first year of follow-up (Figure 
13). The risk remained significantly elevated even after controlling for age, gender, 
baseline cognition, Ca2+, creatinine and APOE4. 
 
 
Figure 13 Risk ratios (RR) and 95% confidence intervals (T-bars) for cognitive decline in 
patients with elevated parathyroid hormone (≥ 62 ng/l, quartile IV) in a series of 
logistic regression models. ● RR for cognitive decline within the first year of follow-
up with the MMSE, × RR for cognitive decline within the first year of follow-up with 
the CDR, ♦ RR for cognitive decline within five years of follow-up with the CDR.  
Model 1 = Unadjusted. Model 2 = Adjusted for age, gender, baseline MMSE or CDR, 
apolipoprotein E allele 4, ionized calcium, and creatinine. 
The five-year CDR assessment was completed in 56.9% of persons, in whom 28% had 
experienced cognitive decline. The MMSE was not used for the assessment of cognition at 
the five-year examination. Again, an elevated baseline PTH concentration predicted a 3-
fold higher risk for cognitive decline (Figure 13). The significance (P = 0.025) also 
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remained after controlling for confounders. Furthermore, the predictive value of elevated 
PTH was consistent in subgroup analysis (Figure 14).  
 
 
Figure 14 Unadjusted risk ratios (95%CIs with error bars) for cognitive decline according to 
the Mini-Mental State Examination (MMSE, decrease in score ≥ 4) and Clinical 
Dementia Rating (CDR, increase in class ≥ 1) within one- and five-year follow-ups in 
patients with an elevated PTH concentration (≥ 62 ng/l). Patients were stratified by 
baseline age, gender, the presence of apolipoprotein E allele 4 (APOE4), median 
levels of ionized calcium (Ca2+) and the estimated glomerular filtration rate (GFR) ● 
RR for cognitive decline within the first year of follow-up with the MMSE, × RR for 
cognitive decline within the first year of follow-up with the CDR, ♦ RR for cognitive 
decline within five years of follow-up with the CDR. 
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6. DISCUSSION 
6.1 Main observations 
This series of studies revealed that in older people without overt renal failure or severe 
hypercalcaemia, serum 25-OHD and PTH were closely associated, but this relationship 
was also affected by age and chronic immobility. Furthermore, a substantial proportion of 
old chronically bedridden patients did not respond to vitamin D deficiency by elevating 
PTH, and the effect of a high-dose six-month cholecalciferol supplementation on the PTH 
concentration was minor. This study demonstrated longitudinally for the first time that the 
absence of secondary hyperparathyroidism also persisted over time.  
The second major finding of the present study was that even a subtle elevation of PTH 
to high-normal levels predicted impaired long-term health outcomes. Slightly elevated 
PTH concentrations indicated an increased risk of clinically significant cognitive decline 
and death during the last years of life in a general aged population. This association was 
also independent of serum ionized calcium (Ca2+) and the estimated glomerular filtration 
rate (GFR). A slightly elevated PTH also indicated impaired two-year survival, even 
during the terminal years of frail elderly subjects, independent not only of Ca2+ and GFR, 
but even of 25-OHD levels. 
6.2 Relationship between PTH and 25-OHD concentrations 
According to the systematic meta-analysis of the present study (Study I), both older age 
and immobility associated with a blunted increase in the PTH concentration during 
vitamin D deficiency and with an attenuated response of PTH levels to vitamin D 
supplementation. These results accord well with previous cross-sectional studies showing 
associations between immobility and blunted PTH (Sorva et al. 1994, Bischoff et al. 1999, 
Sato et al. 1999, Chen et al. 2006), as well as age and attenuated elevation of PTH levels 
(Reginster et al. 1998). However, previous studies have not addressed the confounding 
role of age and immobility on the responses of PTH to vitamin D supplementation. The 
results of the present study suggest that the assumed health benefits of vitamin D 
supplementation mediated by lowering of PTH may also be compromised in disabled 
older persons. However, vitamin D supplementation should be considered, even in these 
patients, due to the well documented muscle effects of vitamin D, which are assumed to be 
independent of PTH (Bischoff-Ferrari et al. 2009b, Ceglia 2009).  
This study also revealed that normal or low-normal PTH levels, i.e. blunted PTH, were 
persistent over time. Blunted PTH was originally described in cross-sectional studies of 
aged hip fracture patients, and prevalences of 53.9% and 52.5% were observed (Sahota et 
al. 2001, Fisher & Davies 2006). Recently, observations of blunted PTH have been 
reported in relatively large samples of postmenopausal women (N = 405, median age 50 
years) and also in vitamin D insufficient subgroups (N = 516, mean age 54 years) of 
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population-based cohorts (Rejnmark et al. 2008, Gunnarsson et al. 2009). Rejnmark et al. 
observed that PTH levels were below approximately 40 ng/l in 63.4% of patients with 25-
OHD below 50 nmol/l. The prevalence of blunted PTH (~ 75%) was even higher in the 
present study (Study II). However, the upper reference limit for PTH was 72 ng/l in the 
long-term care inpatients (Study II). Nevertheless, the high prevalence of blunted PTH is 
well in line with another Finnish study on institutionalized middle-aged patients (N = 138, 
mean age 47 years) with intellectual disability (Kilpinen-Loisa et al. 2009). The blunted 
PTH response has additionally been demonstrated in the oldest of the elderly. Up to 35% 
of Italian centenarians (N = 104) had PTH levels within laboratory reference levels, 
despite severe vitamin D deficiency (25-OHD levels below 5 nmol/l in 95% of cases) 
(Passeri et al. 2003). It can be argued that blunted PTH could be a short-term phenomenon 
due to recently and/or suddenly impaired vitamin D stores. However, blunted PTH 
emerged as a persistent phenomenon in the present study (Study II), and to the best of our 
knowledge, this is the only study so far that has addressed the stability of blunted PTH 
over time. Furthermore, the rapid regulation of PTH concentrations in physiological 
conditions does not support the delayed response to vitamin D deficiency. Thus, it is clear 
that the blunted PTH response to vitamin D deficiency is a common and persistent 
phenomenon in elderly patients with different medical conditions.  
The associations of low PTH with a lower BMI, elevated ICTP and with a tendency for 
lower creatinine observed in the present study also suggest that low PTH in 
hypovitaminosis D is characteristic of frail and immobile patients in a catabolic state. 
Unloading of bones has additionally been shown to result in the release of calcium into 
circulation from bones (Chen et al. 2006, Bischoff et al. 1999), which may partly explain 
the blunted PTH of these patients. In fact, hyperparathyroidism has been associated with 
sarcopenia and falls, as PTH may stimulate muscle protein breakdown (Visser et al. 2003). 
Furthermore, high PTH has been associated with increased adiposity, and a causal 
relationship has been suggested through decreased lipolysis caused by an increased PTH-
related flux of calcium into adipocytes (Rejnmark et al. 2008). Moreover, vitamin D 
status, osteocalcin, calcium, P, and insulin have been reported to explain only a small 
proportion (18%) of this association (Pitroda et al. 2009). Thus, chronic elevation of 
parathyroid function may increase the risk of disability and ultimately chronic immobility, 
partly through the stimulation of muscle protein breakdown leading to decreased muscle 
strength and through the accumulation of body fat, causing an increased burden to 
weakening muscles. Finally, chronic immobility results in excess calcium flux from 
bones, causing suppression of the originally elevated PTH levels. 
In addition to chronic immobilisation, smoking and alcohol intake have been 
associated with blunted PTH (Fisher et al. 2010). However, among the long-term 
inpatients (Study II) there were no active smokers or drinkers. Several age-dependent 
alterations in vitamin D and PTH metabolism have also been presented (Oudshoorn et al. 
2009, Fisher et al. 2010). These may include age-related impairment of renal 1-alpha 
hydroxylation of 25-OHD to calcitriol, abnormalities of the 1.25-OHD receptor, and 
intracellular magnesium depletion leading to impaired PTH synthesis. Furthermore, sex 
hormone differences have been suggested as confounding factors of the PTH-vitamin D 
axis (Gunnarsson et al. 2009). A blunted PTH response to vitamin D deficiency during 
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winter was also found to be more common in a small sample of multiple sclerosis patients 
(N = 23) than in healthy controls (Soilu-Hänninen et al. 2009).  
In recent years, new proteins involved in PTH regulation and actions have been 
discovered, such as fibroblast growth factor 23 (FGF-23), klotho, and Pin1 (Oudshoorn et 
al. 2009, Razzaque 2009, Nechama et al. 2009, Naveh-Many 2010). These proteins, 
particularly Pin1, appear to have key regulatory roles in PTH synthesis and secretion. 
Thus, age and/or disease-related changes in the functioning of these novel regulators of 
PTH may also result in an altered relationship between vitamin D and PTH.  
6.3 Parathyroid hormone as an indicator of impaired survival 
In this study, elevated PTH consistently predicted impaired survival in both a general aged 
population and in frail older long-term care inpatients (Studies IV and V). Furthermore, 
the predictive value of elevated PTH proved to be more important than 25-OHD in the 
older inpatients with a high prevalence of vitamin D deficiency. In comparison with 
previous trials on selected populations (Carlstedt et al 1997, Sambrook et al. 2004, Fisher 
et al. 2007, Chen et al. 2008), the present study expands the results from a general aged 
population to severely disabled long-term inpatients.  
Interestingly, the independent predictive value has also recently been emphasized by 
others (Premaor et al. 2009, Hagström et al. 2009, Pilz et al. 2010). In the recent work by 
Pilz et al., PTH levels emerged as an independent predictor of mortality and 
cardiovascular events during a median follow-up time of 7.7 years in 3 232 Caucasian 
patients who had undergone coronary angiography at baseline (Piltz et al. 2010). 
Unadjusted Cox proportional HRs (with 95% confidence intervals) in the fourth when 
compared to the first PTH quartile were 2.13 (1.75-2.60) for all-cause and 2.47 (1.92-3.17) 
for cardiovascular mortality. After adjustments for common cardiovascular risk factors, 
these HRs remained significant with 1.71 (1.39-2.10) for all-cause and 2.02 (1.55-2.63) 
for cardiovascular mortality. Among specific cardiovascular events, a particularly strong 
association of PTH with sudden cardiac death was observed. These results are also 
supported by another recent study in a community-based cohort of elderly men (mean age, 
71 years; N = 958) (Hagström et al. 2009). In Cox proportional-hazards models adjusted 
for established cardiovascular risk factors (age, systolic blood pressure, diabetes, smoking, 
body mass index, total cholesterol, high-density lipoprotein cholesterol, antihypertensive 
treatment, lipid-lowering treatment, and a history of cardiovascular disease), higher 
plasma PTH was associated with a higher risk of cardiovascular mortality (HR for a 1-SD 
increase in PTH, 1.38; 95% confidence interval, 1.18 to 1.60; P < 0.001) during a median 
follow-up of 9.7 years. This association remained essentially unaltered in participants 
without previous cardiovascular disease and in those with normal PTH (< 62 ng/l), with no 
other signs of a disturbed mineral metabolism (normal CaT, 2.2 to 2.6 mmol/l; normal 
glomerular filtration rate, >50 ml/min/1.73m2; no vitamin D deficiency, plasma 25-OH 
vitamin D > 37.5 nmol/l). Interestingly, elevated plasma PTH (> 48 ng/l) was estimated to 
account for 20% (95% confidence interval, 10 to 26) of the population-attributable risk 
proportion for cardiovascular mortality. 
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In accordance with our observations in long-term care inpatients, the independent 
prognostic significance of PTH in the institutionalized elderly has recently also been 
demonstrated by another research group (Premaor et al. 2009). Premaor et al. 
prospectively evaluated the association of SHPT with mortality and hospitalization during 
a 6-month period in a cohort of 100 individuals aged between 65 and 102 years living in 
geriatric institutions. Patients with PHPT or in haemodialysis were excluded. Fifty-eight 
percent of the individuals had SHPT, defined as serum PTH > 48 ng/l and normal or low 
CaT. The mean baseline serum 25-OHD level was 31.3 nmol/l. The odds of an individual 
with SHPT dying or being hospitalized was 6.6 (95%CI 0.8–54.6; p = 0.07) and 10.7 
(95%CI 1.3–85.9; p = 0.007), respectively. SHPT and BMI were independently associated 
with the combined outcome, after correction for the GFR and 25-OHD. 
Furthermore, in addition to mortality, Fisher et al. detected an association between 
elevated PTH and multiple poor short-term health outcomes in a follow-up study of their 
original hip fracture population (Fisher et al. 2009). They found that SHPT, but not 
vitamin D deficiency, was associated with older age, a higher prevalence of trochanteric 
fractures, coronary artery disease, hypertension, previous stroke and renal impairment, 
increased levels of serum osteocalcin, bone-specific alkaline phosphatase and adiponectin, 
as well as a significantly higher in-hospital mortality (11.8 vs. 0.54%, p = 0.001), 
perioperative myocardial injury (32.7 vs. 22.5%, p = 0.043), a length of stay (LOS) of 20 
days or more (40.2 vs. 26.9%, P = 0.017), and being discharged to institutional care (29.5 
vs. 14.6%, P = 0.019). In multivariate regression analyses, SHPT strongly associated with 
in-hospital mortality and a LOS of 20 days or more. The conclusion of Fisher et al. was 
that vitamin D deficiency was common, but did not per se predict the poor health 
outcomes of patients, further supporting the independent role of PTH. 
Two new papers based on large cohorts of community dwelling elderly with PTH and 
25-OHD measurements and with long follow-up times have also been published very 
recently (Jassal et al. 2010, Cawthon et al. 2010). In line with the results of this thesis, 
Cawthon et al. reported an increased risk of mortality with increasing PTH concentration 
in both a crude and fully adjusted models, but not with decreasing 25-OHD in older men 
(N = 1490, mean age = 73.7 years) participating in an observational osteoporosis study. In 
contrast, Jassal et al. found no relationship between either PTH or 25-OHD and survival in 
a prospective study of Caucasian, middle-income, community-dwelling older men and 
women (N = 1073, mean age = 74 years) living in sunny southern California. The main 
difference between these studies was in the vitamin D status. Cawthon et al. (2010) 
reported a 64% prevalence of 25-OHD values below 75 nmol/l, the respective figure being 
only 14% in the study of Jassal et al. (2010).  
6.4 Role of parathyroid hormone in cognitive decline     
The literature concerning the association of cognition and PTH levels has been scarce and 
mostly concentrated on mental disorders related to vitamin D deficiency, PHPT or renal 
failure. The elevated serum calcium and PTH concentrations closely related to advanced 
primary hyperparathyroidism have been observed to associate with neuropsychiatric 
 
 
 
 
61
symptoms, and case reports have further demonstrated that these cognitive symptoms are 
dramatically improved after parathyroidectomy (Logullo et al. 1998, Papageorgiou et al. 
2008). Recently, parathyroidectomy has additionally been shown to improve the cognition 
of SHPT patients with renal failure (Chou et al. 2008). Interestingly, the association 
between increased parathyroid hormone levels and cognitive decline was not explained by 
hypercalcaemia or impaired renal function in the present study (Study VI), again 
suggesting a more independent role of PTH in the pathophysiology of memory loss. 
However, the present study lacked data on 25-OHD.  
In a cross-sectional study of 752 French women, a subset of an observational 
prospective multicentre cohort study designed to evaluate risk factors for hip fractures 
among community-dwelling women aged 75 years and older, vitamin D levels below 25 
nmol/l, but not PTH concentrations, independently associated with poorer cognitive 
performance (Annweiler et al. 2010b). Furthermore, in another cross-sectional 
investigation of vitamin D stores, dementia, and MRI measures of cardiovascular disease 
(white matter hyperintensity volume, grade, and prevalence of large vessel infarcts) in 
elderly subjects receiving home care (N = 318, aged 65–99 years), vitamin D deficiency 
(25-OHD < 20 ng/ml) was significantly associated with more than twice the odds of all-
cause dementia (OR = 2.3), Alzheimer disease (OR = 2.5), and stroke (with and without 
dementia symptoms, OR = 2.0) (Buell et al. 2010). Finally, in a cohort study of 1 604 men 
enrolled in the Osteoporotic Fractures in Men Study, with an average follow-up of 4.6 
years, Slinin et al. reported weak independent associations between lower 25-
hydroxyvitamin D levels and baseline global and executive cognitive function or incident 
cognitive decline (Slinin et al 2010). Thus, the association between PTH and cognitive 
decline in the present study could be explained by the neuroprotective effects of vitamin 
D, such as antioxidative mechanisms, neuronal calcium regulation, immunomodulation, 
enhanced nerve conduction and detoxification mechanisms (Buell & Dawson-Hughes 
2008). However, according to a recent systematic review, the data on this topic lack 
consistency (Annweiler et al. 2009). It should also be noted that Buell et al. and Slinin et 
al. did not measure parathyroid hormone levels in their studies. 
 Just recently, the association between 25-OHD levels and the risk of substantial 
cognitive decline was investigated in a secondary analysis of the InCHIANTI population-
based study conducted in Italy between 1998 and 2006 (Llewellyn et al. 2010). The 
multivariate adjusted relative risk of substantial cognitive decline in the MMSE in 
participants who were severely serum 25-OHD deficient (<25 nmol/L) in comparison with 
those with sufficient levels of 25-OHD (≥75 nmol/L) was 1.60 (95%CIs 1.19–2.00). The 
MMSE scores of participants who were severely vitamin D deficient declined by an 
additional 0.3 points per year more than those with sufficient levels of 25-OHD. Llewellyn 
et al. also observed that the relative risk for a substantial decline in Trail-Making Test B, 
another formal measure of cognition, was again consistently increased (RR = 1.31, 
95%CIs 1.03–1.51) among those who were severely 25-OHD deficient compared with 
those with sufficient levels of 25-OHD. The long follow-up of this study and the 
evaluation of cognitive decline with two different formal tools strengthen the current data 
on this association. However, Llewellyn et al. also failed to quantify the effect of PTH 
levels in their observations. 
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6.5 Is an elevated PTH concentration a risk indicator or a risk 
factor? 
The question now arises whether an elevated PTH level is a risk indicator or a risk factor 
of poor health outcomes. In other words, 1) does PTH directly cause the poor health 
outcomes, 2) is the elevation of PTH secondary to underlying disease that is also 
responsible for the outcomes, or 3) are PTH levels and a deterioration in health parallel 
phenomena not causally related to each other?  
Even though the evidence is accumulating from epidemiological studies that PTH acts 
as an independent predictor for impaired survival and increased cardiovascular mortality, 
in particular, it may well be that the variables used to adjust for the underlying diseases are 
not sufficiently accurate. For example, all of the studies reporting PTH as an independent 
predictor of mortality (Carlstedt et al. 1997, Sambrook et al. 2004, Fisher et al. 2007, 
Hagström et al 2009, Premaor et al. 2009, Pilz et al. 2010), except the present study 
(Studies IV-VI), have used albumin-adjusted calcium or total calcium instead of the 
ionized fraction to control for calcaemic disorders. However, it is well known that such 
methods do not match the accuracy of direct measurement of Ca2+ (Björkman et al. 2009). 
Similarly, the epidemiological studies, including the present study, use estimated instead 
of directly measured GFR to adjust for renal function. Furthermore, few studies have 
provided data on 25-OHD or 1.25-OHD levels. Thus, it is possible that the impaired health 
outcomes statistically associated with elevated PTH levels are nevertheless clinically 
explained by the age-related loss of renal function, vitamin D deficiency and disturbances 
in mineral metabolism, such as PHPT. In fact, Zittermann et al. recently demonstrated that 
the survival of end-stage heart failure patients was more closely related to 1.25-OHD 
concentrations than PTH levels (Zittermann et al. 2009). Semba et al. also observed no 
relationship between PTH and mortality in community dwelling elderly women, whereas a 
significant association was found with 25-OHD (Semba et al. 2009). Furthermore, despite 
the fact that many of the factors related to metabolic syndrome and cardiovascular disease 
have been associated with PTH (Ahlström et al. 2009), evidence of a causal relationship 
remains scarce. PTH has also been associated with an age-related loss of muscle mass and 
strength (Visser et al. 2003), but again the interaction with the muscle effects of vitamin D 
(Bischoff-Ferrari et al. 2009b, Ceglia 2009) makes interpretations difficult.  
Recent studies have additionally revealed that factors other than renal function, Ca2+ 
and vitamin D are involved in the regulation of parathyroid function. These include such 
factors as FGF-23, klotho and Pin1. FGF-23 has been demonstrated to predict mortality 
independently of PTH levels in haemodialysis patients (Gutierrez et al. 2008), but yet 
again the authors failed to quantify the possible effect of klotho, a co-receptor of FGF-23, 
and a high dietary intake of P, which has also been associated with impaired survival in 
renal failure patients. In addition, Pin1 is an important regulator of PTH gene expression 
(Naveh-Many 2010). Moreover, increased parathyroid gland PTH levels and circulating 
serum PTH concentrations have been recorded in Pin1-knockout mice without changes in 
serum Ca2+ and P levels (Nechama et al. 2009). Most interestingly, Pin1 has been 
associated with telomere maintenance (Lee et al. 2009) and neurodegenerative disorders, 
including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and 
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frontotemporal dementia associated with parkinsonism linked to chromosome 17 
(Rudrabhatla & Pant 2010). However, further studies are required to determine whether 
these associations also explain the predictive value of elevated PTH for mortality and 
cognitive decline in the present study. 
Despite these concerns, some evidence supports the direct involvement of PTH in the 
pathophysiology of the poor health outcomes. Firstly, PTH receptors are abundantly 
expressed in the heart and brain (Reppe et al. 2007). Secondly, experimental studies on 
both animals and humans have reported direct cardiovascular effects of parathyroid 
hormone, including myocardial damage (Bogin et al. 1981), hypertension (Hulter et al. 
1986), a prosclerotic effect on vascular smooth muscle cells (Perkovic et al. 2003) and 
accelerated decompensation following left ventricular hypertrophy (Cha et al. 2010). On 
the other hand, PTH has been associated with an improved mechanical response of 
cardiomyocytes to electrical stimulation (Tastan et al. 2009) and protective effects through 
the activation of bone marrow derived stem cells resulting in a reduction in perfusion 
defects in an experimental animal model of cardiac ischemia (Huber et al. 2010). 
However, these results may not necessarily be in contradiction with each other, because in 
bone physiology and in osteoporotic bone, PTH exerts both anabolic and catabolic effects 
(Neer et al. 2001, Lotinun et al. 2002). 
Because of the close relationship between increased parathyroid function and 
cardiovascular mortality (Hagström et al. 2009, Pilz et al. 2010), it is very interesting that 
PHPT has been associated with several abnormalities that characterize the metabolic 
syndrome, including dyslipidaemia, obesity, insulin resistance and hypertension (Kumar et 
al. 1994, Hagström et al. 2002, Procopio et al. 2003, Bolland et al. 2005). These 
abnormalities are also well established risk factors for cardiovascular diseases and 
subsequent cardiovascular mortality. Furthermore, these metabolic abnormalities have 
been reported to associate more closely with PTH than with CaT levels in a random cohort 
of normocalcaemic 70-year-old community-dwelling people, even after controlling for 
renal function (Ahlström et al. 2009). In fact, according to another previous hypothesis, 
elevated PTH rather than elevated calcium is the main explanation for the association 
between PHPT and the increased risk of cardiovascular diseases (Gotoh et al. 2005, Jorde 
et al. 2005, Hagström et al. 2007, Snijder et al. 2007). Most importantly, the results of 
Ahlström et al. did not change when PHPT patients were excluded. This observation also 
supports the independent role for even subtle elevation of PTH levels as a cardiovascular 
outcome indicator. It should be noted, however, that Ahlström et al. measured the 
calcaemic status by albumin adjustment of CaT, which is well known for its inaccuracy 
compared to the direct measurement of Ca2+ (Björkman et al. 2009). Nevertheless, in our 
random sample of older persons, directly measured Ca2+ concentrations did not correlate 
with the characteristics of the metabolic syndrome addressed by Ahlström et al., whereas 
PTH concentrations correlated inversely with BMI and showed a reverse U-shaped 
relationship with both diastolic and systolic blood pressure (unpublished univariate 
analysis). Although this observation is not fully consistent with Ahlström et al., possibly 
because of the markedly older subjects, it does, however, emphasize the possible role of 
parathyroid function over calcium concentrations in the pathophysiology of the metabolic 
syndrome.  
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Interestingly, it has also been hypothesized that since the cardiac effects of PTH are 
mediated by GPCRs that activate PLC, it is reasonable to presume that a sufficient 
concentration of PTH can be arrhythmogenic in the ischemic heart (McCarty et al. 2009). 
This hypothesis is based on evidence from animal studies showing catecholamines, 
angiotensin II, and endothelin to be arrhythmogenic for ischemic myocardium through the 
activation of receptors linked to the activation of PLC (McCarty et al. 2009). Furthermore, 
in a recent prospective large cohort study on angiography patients (N = 3232) controlling 
for common cardiovascular risk factors and disorders of mineral metabolism (GFR, CaT, 
25-OHD, 1.25-OHD, diuretic use), PTH levels above 40 ng/l significantly predicted 
increased all-cause mortality and cardiovascular events (Pilz et al. 2010). Interestingly, in 
line with the hypothesis of McCarty et al. (2009), Pilz et al. (2010) also observed a strong 
correlation between PTH and sudden cardiac deaths. However, even though the study by 
Pilz et al. (2010) was highly detailed in comparison to all previous studies, it lacked data 
on directly measured Ca2+, FGF-23, and Pin1 activity. 
In summary, the causal relationship between PTH and different clinical outcome 
measures remains putative. Intuitively, it also seems unlikely that a single hormone could 
play a substantial role in preventing or ameliorating a diverse range of diseases. 
Experience from other outcome indicators that have been more thoroughly investigated 
also attenuates the enthusiasm to suggest a direct causal role of PTH levels in the 
pathophysiology of increased mortality and cognitive decline at this time. However, 
studies on the effects of PTH-lowering treatments should be vigorously pursued in order 
to further elucidate these associations. 
6.6 Strengths and limitations of the study 
The major strength of this thesis is the study design of each of the substudies. The meta-
analysis, randomized controlled trial and long-term prospective follow-up of a general 
aged population give a strong base for the validity of the results. The consistency between 
the results of the meta-analysis (Study I) and the clinical trial (Study III), as well as 
between the general aged population and long-term inpatients further emphasizes the 
credibility of this thesis. In contrast to previous research, Ca2+ was directly measured, the 
golden standard in the assessment of calcaemic status, in all the follow-up studies (Studies 
IV-VI). Furthermore, the intact PTH levels were determined with the gold standard 
Nichols Institute diagnostic method in the prospective follow-up studies on a general aged 
population (Studies IV and VI). The method used to measure 25-OHD in the chronically 
immobile older inpatients is also one of the most precise methods available. These studies 
have numerous additional strengths, including the exceptionally long follow-up at the end 
of life, with the vast majority of the subjects being followed until death, the complete data 
on end points from the daily updated National Census Records, the strict age limits of the 
three cohorts and the large amount of baseline data, including thorough clinical 
examinations at entry, enabling the results to be controlled for co-morbidity. Furthermore, 
all the analyses of the clinical trial (Study III) were performed according to intention to 
treat.  
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A major limitation of this thesis is the lack of vitamin D data for the general aged 
population. The measurement of the novel regulators of parathyroid function, such as 
FGF-23, klotho and Pin1 activity, in addition to direct measurement of GFR also would 
have considerably strengthened the data. However, there was no access to such 
measurements during data collection due to the lack of analytical methods and resources. 
Despite the observed minor decrease in PTH levels among the long-term care inpatients 
after vitamin D supplementation, the severe dementia and homogeneity of these patients is 
also a limitation for any further investigations on the causal relationship between the 
outcomes and elevated PTH. It could also have been worthwhile to include other databases 
in addition to PubMed in the search for trials to include in the meta-analysis. Furthermore, 
it should be noted that the results of the meta-analysis were driven by the inclusion of 
Study III, which was the largest vitamin D supplementation trial on immobilized elderly 
subjects. It is also possible that the methodological differences in 25-OHD and PTH 
measurement between the trials included in the meta-analysis may have confounded the 
results. However, these limitations are not likely to have a major effect on the conclusions 
of this thesis. 
6.7 Conclusions and future perspectives 
In light of the data presented in thesis, it appears that the interplay between PTH and 
vitamin D in the regulation of calcium homeostasis is more complex than has generally 
been considered. The concurrent results of other research groups also accord well with the 
present study, suggesting that in addition to muskuloskeletal health, PTH is also related to 
the maintenance of other important domains of health in old age. Higher PTH 
concentrations, even within conventional laboratory references, seem to be an independent 
indicator of an increased risk of all-cause and of cardiovascular mortality independently of 
established cardiovascular risk factors, disturbances in mineral metabolism, and renal 
failure. Limited and inconsistent evidence supports the role of a vitamin D deficiency-
related lack of neuroprotective effects over the causal association between PTH and 
impaired cognitive functions. However, the causality of these associations remains 
unclear. The clinical implications of the relationships found remain to be elucidated by 
future studies interfering with PTH concentrations, especially by long-term interventions 
to reduce PTH.  
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